<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cardiac Pharmacology - PiCCO Online Manual</title>
    <link href="https://fonts.googleapis.com/css2?family=Lato:wght@400;700&family=Montserrat:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../CSS/main.css">
    <link rel="stylesheet" href="../CSS/print.css" media="print">
<<<<<<< HEAD
    <link rel="stylesheet" href="../CSS/cards.css">
</head>
<body>
    <div class="nav-overlay" id="nav-overlay"></div>
    <header class="main-header">
=======
    <style>
        :root {
            --cat-v: #ff0044; --cat-i: #00d4ff; --cat-a: #bb00ff;
            --cat-d: #ccff00; --cat-h: #00ff88; --cat-c: #ffaa00; 
            --cat-b: #3d5afe; --cat-s: #ffffff; --cat-r: #795548;
        }

        /* –°—Ç–∏–ª–∏ –¥–ª—è –∫–∞—Ä—Ç–æ—á–µ–∫ –≤ —Å—Ç–∏–ª–µ –ø–µ—Ä–∏–æ–¥–∏—á–µ—Å–∫–æ–π —Ç–∞–±–ª–∏—Ü—ã */
        .drug-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(160px, 1fr));
            gap: 15px;
            margin-top: 30px;
        }

        .drug-card {
            aspect-ratio: 1/1.2;
            border: 1px solid #444;
            background: rgba(255, 255, 255, 0.02);
            display: flex;
            flex-direction: column;
            justify-content: space-between;
            padding: 10px;
            cursor: pointer;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            position: relative;
        }

        .drug-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 20px rgba(0,0,0,0.5);
            border-color: #fff;
            z-index: 10;
        }

        .card-top { font-size: 0.6rem; text-transform: uppercase; opacity: 0.8; font-weight: bold; line-height: 1.1; }
        .card-mid { flex-grow: 1; display: flex; flex-direction: column; justify-content: center; align-items: center; }
        .drug-symbol { font-size: 2.2rem; font-weight: 800; font-family: 'Montserrat'; }
        .drug-name { font-size: 0.75rem; font-weight: 700; text-transform: uppercase; margin-top: 5px; text-align: center; }
        .card-bottom { font-size: 0.65rem; border-top: 1px solid rgba(255,255,255,0.1); padding-top: 5px; margin-top: 5px; line-height: 1.2; }
        .peds-label { color: #00d4ff; font-weight: bold; }

        /* –¶–≤–µ—Ç–æ–≤—ã–µ –∫–∞—Ç–µ–≥–æ—Ä–∏–∏ */
        .cat-v { color: var(--cat-v); border-left: 3px solid var(--cat-v); }
        .cat-i { color: var(--cat-i); border-left: 3px solid var(--cat-i); }
        .cat-a { color: var(--cat-a); border-left: 3px solid var(--cat-a); }
        .cat-d { color: var(--cat-d); border-left: 3px solid var(--cat-d); }
        .cat-h { color: var(--cat-h); border-left: 3px solid var(--cat-h); }
        .cat-c { color: var(--cat-c); border-left: 3px solid var(--cat-c); }
        .cat-b { color: var(--cat-b); border-left: 3px solid var(--cat-b); }
        .cat-s { color: var(--cat-s); border-left: 3px solid var(--cat-s); }
        .cat-r { color: var(--cat-r); border-left: 3px solid var(--cat-r); }

        /* Tooltip —Ä–∞—Å—à–∏—Ä–µ–Ω–Ω—ã–π */
        #tooltip {
            position: fixed; background: var(--bg-color, #0a0a0a); color: var(--text-color, #eee);
            border: 1px solid #555; padding: 20px; width: 450px; display: none; z-index: 3000;
            box-shadow: 0 0 30px rgba(0,0,0,0.8); backdrop-filter: blur(15px);
            max-height: 80vh; overflow-y: auto; border-radius: 4px;
        }
        .tt-title { font-size: 1.6rem; color: #00ffff; font-family: 'Montserrat'; border-bottom: 2px solid #333; padding-bottom: 5px; margin-bottom: 2px; }
        .tt-trade { font-size: 1rem; color: #ff00ff; font-weight: bold; margin-bottom: 15px; display: block; }
        .tt-label { font-size: 0.7rem; color: #888; text-transform: uppercase; display: block; margin-top: 12px; font-weight: bold; letter-spacing: 1px; }
        .tt-content { font-size: 0.9rem; line-height: 1.4; margin-top: 3px; }
        .tt-picco { background: rgba(0, 255, 136, 0.1); border-left: 3px solid #00ff88; padding: 8px; margin-top: 10px; font-style: italic; }

        /* –¢–µ–º–∞ –ø–µ—Ä–µ–∫–ª—é—á–∞—Ç–µ–ª—å */
        .theme-switcher { position: fixed; bottom: 20px; right: 20px; z-index: 1000; padding: 10px; border-radius: 50%; cursor: pointer; }
    </style>
</head>
<body class="dark-theme"> <header class="main-header">
>>>>>>> 423490dbb2ae748f4e57e59325f64b7311c0f258
        <h1 class="site-title"><a href="../index.html" class="site-title"><span class="green-highlighted-oval-3d">PiCCO</span> - <span class="color-red">O</span>nline Manual</a></h1>
        <button class="menu-toggle" id="menu-toggle">‚ò∞</button>
    </header>

    <div class="wrapper container">
        <nav class="main-nav" id="main-nav">
            <h2>Sections</h2>
            <div class="search-container">
<<<<<<< HEAD
                <input type="text" id="searchInput" placeholder="Search sections..." aria-label="Search sections">
=======
                <input type="text" id="searchInput" placeholder="Search sections...">
>>>>>>> 423490dbb2ae748f4e57e59325f64b7311c0f258
            </div>
            <ul>
                <li><a href="introduction.html">Introduction</a></li>
                <li><a href="principles.html">Principles</a></li>
                <li><a href="history.html">History</a></li>
                <li><a href="equipment.html">Equipment</a></li>
                <li><a href="calibration.html">Calibration</a></li>
                <li><a href="indications.html">Indications</a></li>
                <li><a href="contraindications.html">Contraindications</a></li>
                <li><a href="limitations.html">Limitations</a></li>
                <li><a href="pediatric.html">Pediatric considerations</a></li>
                <li><a href="preload.html">Preload</a></li>
                <li><a href="contractility.html">Contractility</a></li>
                <li><a href="lungwater.html">Lung water</a></li>
                <li><a href="afterload.html">Afterload</a></li>
                <li><a href="dynamic.html">Dynamic parameters</a></li>
                <li><a href="derived.html">Derived parameters</a></li>
                <li><a href="algorithms.html">Algorithms</a></li>
                <li><a href="cases.html">Clinical cases</a></li>
                <li><a href="errors.html">Errors</a></li>
                <li><a href="physiology.html">Physiology</a></li>
                <li><a href="reference.html">Reference</a></li>
                <li><a href="faq.html">FAQ</a></li>
                <li><a href="visualizations.html">Visualizations</a></li>
<<<<<<< HEAD
                <li><a href="periodic-table.html">Periodic Table</a></li>
                <li><a href="pharmacology.html" class="active">Pharmacology</a></li>
                <li><a href="about.html">About</a></li>
                <li><a href="simulation.html">Quiz</a></li>
=======
                <li><a href="about.html">About</a></li>
                <li><a href="simulation.html"><span class="gold-highlighted-oval-3d">Quiz üéì</span></a></li>
                <li><a href="piccoworld.html"><span class="green-highlighted-oval-3d">PiCCO</span> WORLD</a></li>
                <li><a href="commondrugs.html"><span class="red-highlighted-oval-3d">Common üßê</span> <span class="pink-highlighted-oval-3d">Drugs</span></a></li>
>>>>>>> 423490dbb2ae748f4e57e59325f64b7311c0f258
            </ul>
        </nav>

        <main class="main-content">
<<<<<<< HEAD
            <h2 class="page-title">Cardiac Pharmacology Reference</h2>
            
            <div class="card-table" id="pharmaTable"></div>
            <div class="tooltip" id="tooltip"></div>
        </main>
    </div>

    <footer class="main-footer">
        <div class="container">
            <p>¬© 2025 <span class="green-highlighted-oval-3d">PiCCO</span> Online Manual</p>
        </div>
    </footer>
    
=======
            <h2 style="text-align: center;"><span class="red-highlighted-oval-3d">Critical Care</span> <span class="pink-highlighted-oval-3d">Pharmacology</span></h2>
            <div class="drug-grid" id="drugGrid"></div>
        </main>
    </div>

    <div id="tooltip"></div>

>>>>>>> 423490dbb2ae748f4e57e59325f64b7311c0f258
    <button class="theme-switcher" id="theme-switcher" aria-label="Toggle theme">
        <span class="icon-sun">‚òÄÔ∏è</span>
        <span class="icon-moon" style="display: none;">üåô</span>
    </button>

    <script>
<<<<<<< HEAD
        const drugs = {
            norepinephrine: {
                category: 'Vasopressor<br>Catecholamine',
                name: 'Norepinephrine',
                symbol: 'Nori',
                receptor: 'Œ±1 > Œ≤1',
                dose: 'Adult: 0.01-3 Œºg/kg/min<br>Peds: 0.05-2 Œºg/kg/min',
                class: 'norepinephrine',
                mechanism: 'Potent Œ±1-adrenergic agonist (vasoconstriction) with moderate Œ≤1 activity (inotropy). Increases SVR and MAP with minimal effect on HR. Acts on vascular Œ±1 receptors causing arteriolar and venous constriction.',
                indications: 'First-line vasopressor for septic shock, cardiogenic shock with low SVR, neurogenic shock, anaphylaxis. Preferred in distributive shock states.',
                contraindications: 'Hypovolemia without adequate fluid resuscitation (relative). Avoid in pheochromocytoma, mesenteric/peripheral vascular thrombosis (relative).',
                sideeffects: 'Tissue necrosis if extravasation, bradycardia (reflex), arrhythmias, digital/limb ischemia at high doses, increased myocardial oxygen demand.',
                remarks: 'GOLD STANDARD for septic shock. Requires central line (can use peripheral temporarily). Monitor tissue perfusion (lactate, ScvO‚ÇÇ). Titrate to MAP ‚â•65 mmHg. Can cause reflex bradycardia via baroreceptor activation. DO NOT mix with alkaline solutions.'
            },
            epinephrine: {
                category: 'Vasopressor<br>Inotrope',
                name: 'Epinephrine',
                symbol: 'Epi',
                receptor: 'Œ±1, Œ≤1, Œ≤2',
                dose: 'Adult: 0.01-0.5 Œºg/kg/min<br>Peds: 0.01-1 Œºg/kg/min<br>Bolus: 1 mg IV (arrest)',
                class: 'epinephrine',
                mechanism: 'Non-selective Œ± and Œ≤ agonist. Low doses (<0.05): Œ≤1/Œ≤2 effects (inotropy, chronotropy, bronchodilation). High doses: Œ±1 predominates (vasoconstriction). Increases CO, HR, SVR, myocardial contractility.',
                indications: 'Anaphylaxis (IM 0.3-0.5mg), cardiac arrest, severe bradycardia, refractory shock not responding to norepinephrine, post-cardiac surgery low CO state, Œ≤-blocker overdose.',
                contraindications: 'No absolute contraindications in life-threatening situations. Relative: uncontrolled tachyarrhythmias, coronary insufficiency.',
                sideeffects: 'Tachycardia, arrhythmias (VT/VF), myocardial ischemia, hyperglycemia, hypokalemia, lactic acidosis (Œ≤2-mediated), pulmonary edema, tissue necrosis if extravasation.',
                remarks: 'HIGHLY arrhythmogenic - continuous ECG monitoring essential. Causes significant increase in myocardial O‚ÇÇ consumption. May worsen lactate due to Œ≤2-mediated aerobic glycolysis (type B lactic acidosis) - do not interpret elevated lactate as worsening shock. Use with extreme caution in coronary disease. First-line for anaphylaxis (IM route).'
            },
            vasopressin: {
                category: 'Vasopressor<br>ADH analog',
                name: 'Vasopressin',
                symbol: 'Vaso',
                receptor: 'V1, V2',
                dose: 'Adult: 0.01-0.04 U/min<br>Peds: 0.0003-0.002 U/kg/min',
                class: 'vasopressin',
                mechanism: 'V1 receptor agonist ‚Üí vascular smooth muscle contraction. V2 receptor ‚Üí renal water reabsorption. Non-adrenergic vasoconstrictor. Maintains vasomotor tone in catecholamine-refractory shock (restores vascular sensitivity).',
                indications: 'Septic shock refractory to norepinephrine, vasodilatory shock post-cardiac surgery, cardiac arrest (alternative to epinephrine), diabetes insipidus, GI bleeding (terlipressin preferred).',
                contraindications: 'Coronary artery disease (relative - may cause coronary vasoconstriction), advanced vascular disease. No dose titration - fixed dose only.',
                sideeffects: 'Digital/splanchnic ischemia, hyponatremia (water retention), coronary vasoconstriction, decreased CO, bradycardia, arrhythmias, skin necrosis, decreased platelet count.',
                remarks: 'Used as ADJUNCT to norepinephrine, NOT monotherapy. FIXED DOSE (0.03-0.04 U/min in adults) - do not titrate. May allow reduction of catecholamine doses (catecholamine-sparing). Particularly useful in septic shock with relative vasopressin deficiency. Does NOT increase HR (unlike catecholamines). May worsen cardiac output in cardiogenic shock. Monitor for mesenteric ischemia.'
            },
            phenylephrine: {
                category: 'Vasopressor<br>Pure Œ±-agonist',
                name: 'Phenylephrine',
                symbol: 'Neo',
                receptor: 'Œ±1',
                dose: 'Adult: 0.5-3 Œºg/kg/min<br>Bolus: 50-200 Œºg<br>Peds: 0.5-3 Œºg/kg/min',
                class: 'phenylephrine',
                mechanism: 'Pure Œ±1-adrenergic agonist. Increases SVR via arterial vasoconstriction. NO direct cardiac effects (no Œ≤ activity). May decrease CO via reflex bradycardia and increased afterload.',
                indications: 'Hypotension during anesthesia, temporary support during norepinephrine preparation, supraventricular tachycardia (reflex bradycardia), patients with tachyarrhythmias where Œ≤-agonists undesirable.',
                contraindications: 'Severe hypertension, ventricular tachycardia. Use cautiously in coronary disease, heart failure (increases afterload ‚Üí may worsen CO).',
                sideeffects: 'Reflex bradycardia, decreased CO, increased afterload, headache, hypertension, tissue necrosis with extravasation.',
                remarks: 'PURE vasoconstrictor - NO inotropic support. May DECREASE cardiac output due to increased afterload. Useful for brief blood pressure support or in tachycardic patients. Can cause significant bradycardia (baroreceptor reflex). NOT ideal for prolonged shock support - norepinephrine preferred. Good for anesthesia-induced hypotension (bolus dosing).'
            },
            dopamine: {
                category: 'Vasopressor<br>Inotrope',
                name: 'Dopamine',
                symbol: 'Dopa',
                receptor: 'D, Œ≤, Œ±',
                dose: 'Adult: 2-20 Œºg/kg/min<br>Peds: 2-20 Œºg/kg/min',
                class: 'dopamine',
                mechanism: 'Dose-dependent effects. Low (2-5): D1/D2 receptors ‚Üí renal/splanchnic vasodilation. Medium (5-10): Œ≤1 ‚Üí inotropy/chronotropy. High (>10): Œ±1 ‚Üí vasoconstriction. Precursor to norepinephrine.',
                indications: 'Bradycardia with hypotension (alternative to atropine/pacing), cardiogenic shock (historically - dobutamine now preferred), shock in bradycardic patients.',
                contraindications: 'Pheochromocytoma, uncorrected tachyarrhythmias, hypovolemia. Avoid in tachydysrhythmias.',
                sideeffects: 'Tachycardia (dose-limiting), arrhythmias (VT/VF), myocardial ischemia, increased pulmonary shunting, tissue necrosis, nausea/vomiting.',
                remarks: 'LARGELY REPLACED by norepinephrine due to higher arrhythmia risk. "Renal-dose dopamine" (2-5 Œºg/kg/min) is NOT supported by evidence and NOT recommended. MORE arrhythmogenic than norepinephrine. May increase mortality in cardiogenic shock compared to norepinephrine. Useful in bradycardic shock. Unpredictable effects due to dose-dependent receptor activity.'
            },
            terlipressin: {
                category: 'Vasopressor<br>ADH analog',
                name: 'Terlipressin',
                symbol: 'Terli',
                receptor: 'V1',
                dose: 'Adult: 1-2 mg bolus q4-6h<br>Peds: Limited data',
                class: 'terlipressin',
                mechanism: 'Vasopressin analog, V1 receptor agonist. Prodrug converted to lysine-vasopressin. Longer half-life than vasopressin (4-6h vs 10-20min). Splanchnic vasoconstriction.',
                indications: 'Hepatorenal syndrome, variceal bleeding, septic shock (less common than vasopressin), catecholamine-refractory shock.',
                contraindications: 'Coronary artery disease, peripheral vascular disease, pregnancy.',
                sideeffects: 'Myocardial ischemia, arrhythmias, mesenteric ischemia, hyponatremia, skin necrosis, bradycardia.',
                remarks: 'PRIMARILY used for variceal bleeding and hepatorenal syndrome. Longer duration allows bolus dosing vs continuous infusion. Significant risk of ischemic complications. Less commonly used than vasopressin in general ICU settings. NOT available in all countries (not FDA approved in USA).'
            },
            dobutamine: {
                category: 'Inotrope<br>Œ≤-agonist',
                name: 'Dobutamine',
                symbol: 'Dobu',
                receptor: 'Œ≤1 > Œ≤2',
                dose: 'Adult: 2-20 Œºg/kg/min<br>Peds: 2-20 Œºg/kg/min',
                class: 'dobutamine',
                mechanism: 'Synthetic catecholamine. Primarily Œ≤1-agonist (inotropy, chronotropy) with mild Œ≤2 (vasodilation) and Œ±1 effects. Increases CO and SV. Decreases SVR and PCWP. Improves myocardial contractility.',
                indications: 'Cardiogenic shock, acute decompensated heart failure with low CO, stress testing (pharmacologic), right ventricular failure, weaning from cardiopulmonary bypass.',
                contraindications: 'Hypertrophic obstructive cardiomyopathy, aortic stenosis (severe), uncorrected hypovolemia, tachydysrhythmias, acute MI with hypotension.',
                sideeffects: 'Tachycardia, increased myocardial O‚ÇÇ demand, arrhythmias, hypotension (Œ≤2 vasodilation), myocardial ischemia, hypokalemia.',
                remarks: 'INOTROPE of choice for cardiogenic shock with adequate BP. May DECREASE blood pressure due to Œ≤2-mediated vasodilation - combine with vasopressor if hypotensive. Increases myocardial oxygen consumption - monitor for ischemia. Can worsen hypotension in severe shock - norepinephrine often added. Tachyphylaxis develops after 48-72h. NOT for distributive shock.'
            },
            milrinone: {
                category: 'Inotrope<br>PDE-3 inhibitor',
                name: 'Milrinone',
                symbol: 'Milri',
                receptor: 'PDE3i',
                dose: 'Adult: Load 50 Œºg/kg, then 0.375-0.75 Œºg/kg/min<br>Peds: 0.25-0.75 Œºg/kg/min',
                class: 'milrinone',
                mechanism: 'Phosphodiesterase-3 inhibitor ‚Üí increases cAMP. Positive inotropy (increased contractility) AND vasodilation (afterload reduction). Lusitropic effect (improved diastolic relaxation). Does NOT increase O‚ÇÇ consumption like Œ≤-agonists.',
                indications: 'Advanced heart failure refractory to dobutamine, right ventricular failure, pulmonary hypertension with RV dysfunction, post-cardiac surgery low CO, decompensated heart failure, cardiogenic shock.',
                contraindications: 'Severe aortic/pulmonary stenosis, hypovolemia, severe hypotension. Caution in renal failure (accumulation).',
                sideeffects: 'Hypotension (vasodilation), arrhythmias (especially ventricular), thrombocytopenia, headache, hypokalemia. May increase mortality in chronic use.',
                remarks: 'INODILATOR - both inotrope and vasodilator. EXCELLENT for RV failure and pulmonary hypertension. Does NOT work via adrenergic receptors - effective even with Œ≤-blocker use. Long half-life (2-3h) - effects persist after stopping. LOADING DOSE often omitted to avoid hypotension. Useful when dobutamine causes excessive tachycardia. May worsen hypotension - often combined with norepinephrine. Prolonged use associated with increased mortality in chronic HF trials.'
            },
            levosimendan: {
                category: 'Inotrope<br>Ca-sensitizer',
                name: 'Levosimendan',
                symbol: 'Levo',
                receptor: 'Ca++',
                dose: 'Adult: Load 6-12 Œºg/kg, then 0.05-0.2 Œºg/kg/min<br>Peds: 0.05-0.2 Œºg/kg/min',
                class: 'levosimendan',
                mechanism: 'Calcium sensitizer - increases troponin C sensitivity to Ca¬≤‚Å∫ WITHOUT increasing intracellular calcium. Also opens ATP-dependent K‚Å∫ channels ‚Üí vasodilation. Does NOT increase myocardial O‚ÇÇ consumption. Active metabolites last 7-9 days.',
                indications: 'Acute decompensated heart failure, cardiogenic shock, post-cardiac surgery low CO, septic cardiomyopathy. NOT available in USA.',
                contraindications: 'Severe hypotension (SBP <90), severe tachycardia, mechanical obstruction (HOCM, severe stenosis), severe renal/hepatic impairment.',
                sideeffects: 'Hypotension (common), tachycardia, arrhythmias, headache, hypokalemia. Hypotension may require vasopressor support.',
                remarks: 'UNIQUE mechanism - calcium sensitization. Very long duration due to active metabolites (OR-1896). Does NOT increase O‚ÇÇ consumption (unlike catecholamines) - safer in ischemic hearts. Often requires norepinephrine co-administration for hypotension. LOADING DOSE often omitted or reduced to minimize hypotension. May improve outcomes vs dobutamine in some studies. NOT FDA approved in USA. Preferred in cardiac surgery in some European centers.'
            },
            digoxin: {
                category: 'Inotrope<br>Cardiac glycoside',
                name: 'Digoxin',
                symbol: 'Dig',
                receptor: 'Na/K',
                dose: 'Adult: Load 0.5-1 mg, Maint 0.125-0.25 mg/day<br>Peds: Load 15-30 Œºg/kg, Maint 5-10 Œºg/kg/day',
                class: 'digoxin',
                mechanism: 'Na‚Å∫/K‚Å∫-ATPase inhibitor ‚Üí increased intracellular Ca¬≤‚Å∫ ‚Üí positive inotropy. Vagal effects: slows AV conduction, negative chronotropy. Positive inotropy + negative chronotropy.',
                indications: 'Atrial fibrillation with rapid ventricular response (rate control), chronic heart failure with reduced EF, supraventricular tachycardias.',
                contraindications: 'Ventricular fibrillation, AV block (2nd/3rd degree without pacemaker), WPW with AF, hypertrophic cardiomyopathy, acute MI.',
                sideeffects: 'Arrhythmias (ANY type possible), AV block, bradycardia, nausea, visual changes (yellow/green halos), confusion, hyperkalemia in toxicity.',
                remarks: 'NARROW therapeutic window (0.5-2 ng/mL). MANY drug interactions. Toxicity risk increased by hypokalemia, hypomagnesemia, hypercalcemia, renal failure. Does NOT reduce mortality in HF - only symptomatic benefit. Primarily used for rate control in AF. Toxicity can cause ANY arrhythmia. Monitor levels, renal function, electrolytes. DigiFab for severe toxicity.'
            },
            isoproterenol: {
                category: 'Inotrope<br>Pure Œ≤-agonist',
                name: 'Isoproterenol',
                symbol: 'Iso',
                receptor: 'Œ≤1, Œ≤2',
                dose: 'Adult: 0.5-10 Œºg/min<br>Peds: 0.05-0.5 Œºg/kg/min',
                class: 'isoproterenol',
                mechanism: 'Pure Œ≤1 and Œ≤2 agonist (NO Œ± activity). Powerful chronotrope and inotrope. Decreases SVR (Œ≤2). Increases HR, contractility, and CO. Profound vasodilation.',
                indications: 'Refractory bradycardia (bridge to pacing), torsades de pointes, Œ≤-blocker/calcium channel blocker overdose, temporary support for heart transplant denervated heart.',
                contraindications: 'Tachyarrhythmias, coronary insufficiency, digitalis toxicity.',
                sideeffects: 'Severe tachycardia, arrhythmias, myocardial ischemia, hypotension (vasodilation), increased myocardial O‚ÇÇ demand.',
                remarks: 'RARELY used - very arrhythmogenic. Massive increase in myocardial O‚ÇÇ consumption. May cause severe hypotension due to vasodilation despite increased CO. Useful for bradycardia when pacing not immediately available. Historical use in heart transplant patients (denervated hearts). AVOID in ischemic heart disease.'
            },
            metoprolol: {
                category: 'Œ≤-blocker<br>Œ≤1-selective',
                name: 'Metoprolol',
                symbol: 'Meto',
                receptor: 'Œ≤1',
                dose: 'Adult IV: 2.5-5 mg q5min (max 15mg)<br>PO: 25-200 mg BID<br>Peds: 1-2 mg/kg/day',
                class: 'metoprolol',
                mechanism: 'Cardioselective Œ≤1-blocker (Œ≤1 >> Œ≤2). Decreases HR, contractility, AV conduction, myocardial O‚ÇÇ demand. Reduces renin release. Membrane stabilizing effect at high doses.',
                indications: 'Acute coronary syndrome, hypertension, atrial fibrillation (rate control), heart failure (chronic - not acute), post-MI, hypertrophic cardiomyopathy, aortic dissection.',
                contraindications: 'Decompensated heart failure, cardiogenic shock, severe bradycardia, 2nd/3rd degree AV block, sick sinus syndrome, severe asthma/COPD, acute cocaine intoxication.',
                sideeffects: 'Bradycardia, hypotension, bronchospasm, fatigue, depression, masking of hypoglycemia, worsening heart failure, cold extremities.',
                remarks: 'CARDIOSELECTIVE (Œ≤1) but loses selectivity at higher doses. Two formulations: tartrate (IR, BID) and succinate (XL, daily). Mortality benefit in chronic heart failure (MERIT-HF trial). Start LOW dose in HF and titrate slowly. May worsen acute decompensated HF - NOT for acute use. Use cautiously in cocaine-associated chest pain (Œ±-mediated vasoconstriction).'
            },
            esmolol: {
                category: 'Œ≤-blocker<br>Ultra-short acting',
                name: 'Esmolol',
                symbol: 'Esmo',
                receptor: 'Œ≤1',
                dose: 'Adult: Load 500 Œºg/kg, then 50-300 Œºg/kg/min<br>Peds: 100-500 Œºg/kg/min',
                class: 'esmolol',
                mechanism: 'Ultra-short acting cardioselective Œ≤1-blocker. Rapid onset (1-2 min), very short half-life (9 min). Decreases HR and contractility. Metabolized by RBC esterases.',
                indications: 'Perioperative tachycardia/hypertension, supraventricular tachycardia, atrial fibrillation with RVR, acute aortic dissection, thyroid storm, critically ill patients needing titratable Œ≤-blockade.',
                contraindications: 'Same as other Œ≤-blockers: decompensated HF, cardiogenic shock, severe bradycardia, AV block, severe asthma.',
                sideeffects: 'Hypotension (most common), bradycardia, bronchospasm, heart failure exacerbation. Effects resolve quickly after stopping.',
                remarks: 'IDEAL for acute situations requiring rapid titration and reversibility. Very short half-life allows safe titration - effects dissipate within 10-20 min of stopping. Excellent for perioperative use. INFUSION only - not for bolus. Can transition to longer-acting Œ≤-blocker once stable. Useful when unsure if patient will tolerate Œ≤-blockade.'
            },
            propranolol: {
                category: 'Œ≤-blocker<br>Non-selective',
                name: 'Propranolol',
                symbol: 'Prop',
                receptor: 'Œ≤1, Œ≤2',
                dose: 'Adult IV: 0.5-1 mg slow push<br>PO: 10-320 mg/day<br>Peds: 0.5-1 mg/kg/day',
                class: 'propranolol',
                mechanism: 'Non-selective Œ≤-blocker (Œ≤1 and Œ≤2). Membrane stabilizing activity. Decreases HR, contractility, myocardial O‚ÇÇ demand. No intrinsic sympathomimetic activity.',
                indications: 'Hypertension, angina, post-MI, arrhythmias, hypertrophic cardiomyopathy, thyrotoxicosis, essential tremor, migraine prophylaxis, portal hypertension.',
                contraindications: 'Asthma/COPD (Œ≤2 blockade), decompensated HF, bradycardia, AV block, cardiogenic shock, cocaine use.',
                sideeffects: 'Bronchospasm (Œ≤2 blockade), bradycardia, hypotension, fatigue, depression, impotence, hypoglycemia masking, worsening peripheral vascular disease.',
                remarks: 'NON-SELECTIVE - blocks both Œ≤1 and Œ≤2. AVOID in asthma/COPD due to Œ≤2 blockade causing bronchoconstriction. Lipophilic - crosses blood-brain barrier (CNS effects: nightmares, depression). Used for portal hypertension in cirrhosis. NOT preferred for chronic HF (non-selective). Good for thyroid storm (blocks peripheral T4‚ÜíT3 conversion).'
            },
            carvedilol: {
                category: 'Œ≤-blocker<br>Œ±/Œ≤ blocker',
                name: 'Carvedilol',
                symbol: 'Carv',
                receptor: 'Œ≤, Œ±1',
                dose: 'Adult: 3.125-25 mg BID<br>Peds: 0.05-0.4 mg/kg BID',
                class: 'carvedilol',
                mechanism: 'Non-selective Œ≤-blocker + Œ±1-blocker. Vasodilation (Œ±1 blockade) + decreased HR/contractility (Œ≤ blockade). Antioxidant properties. Reduces afterload and preload.',
                indications: 'Chronic heart failure with reduced EF, post-MI LV dysfunction, hypertension.',
                contraindications: 'Decompensated HF, cardiogenic shock, severe bradycardia, AV block, severe hepatic impairment, asthma.',
                sideeffects: 'Hypotension (Œ± blockade), dizziness, bradycardia, fatigue, worsening HF initially, bronchospasm, hyperglycemia.',
                remarks: 'ONLY Œ≤-blocker with proven mortality benefit in HF with Œ±-blocking activity. Vasodilation from Œ±1 blockade helps offset increased afterload from Œ≤ blockade. Start VERY LOW and titrate slowly in HF (3.125 mg BID ‚Üí target 25-50 mg BID). May worsen HF initially - warn patients. Take with food to slow absorption and reduce orthostatic hypotension. Superior to metoprolol in some HF trials.'
            },
            labetalol: {
                category: 'Œ≤-blocker<br>Œ±/Œ≤ blocker',
                name: 'Labetalol',
                symbol: 'Labet',
                receptor: 'Œ≤, Œ±1',
                dose: 'Adult IV: 10-20 mg bolus, then 0.5-2 mg/min<br>PO: 100-400 mg BID<br>Peds: 0.2-1 mg/kg/dose',
                class: 'labetalol',
                mechanism: 'Combined Œ±1 and non-selective Œ≤-blocker (Œ≤:Œ± ratio 7:1 IV, 3:1 PO). Decreases BP via vasodilation (Œ±) and decreased CO (Œ≤). Maintains cerebral/renal blood flow.',
                indications: 'Hypertensive emergency, acute aortic dissection, preeclampsia/eclampsia, perioperative hypertension, pheochromocytoma (after Œ±-blockade).',
                contraindications: 'Asthma/COPD, decompensated HF, bradycardia, AV block, cardiogenic shock, severe hepatic disease.',
                sideeffects: 'Hypotension, bradycardia, bronchospasm, dizziness, nausea, scalp tingling, hepatotoxicity (rare).',
                remarks: 'EXCELLENT for hypertensive emergencies - rapid BP reduction without excessive decrease in cerebral perfusion. SAFE in pregnancy (preeclampsia/eclampsia). Slower onset than nicardipine but more predictable. Bronchospasm risk lower than pure Œ≤-blockers but still present. Useful in aortic dissection (reduces dP/dt). Can be given as repeated boluses or infusion.'
            },
            bisoprolol: {
                category: 'Œ≤-blocker<br>Œ≤1-selective',
                name: 'Bisoprolol',
                symbol: 'Biso',
                receptor: 'Œ≤1',
                dose: 'Adult: 1.25-10 mg daily<br>Peds: Limited data',
                class: 'bisoprolol',
                mechanism: 'Highly cardioselective Œ≤1-blocker. Long half-life (10-12h). No intrinsic sympathomimetic activity. Minimal lipophilicity (less CNS effects).',
                indications: 'Chronic heart failure with reduced EF, hypertension, angina, post-MI.',
                contraindications: 'Decompensated HF, cardiogenic shock, severe bradycardia, AV block, sick sinus syndrome.',
                sideeffects: 'Bradycardia, hypotension, fatigue, dizziness, worsening HF initially.',
                remarks: 'HIGHLY Œ≤1-selective - better tolerated in mild COPD than non-selective agents. Mortality benefit in HF (CIBIS-II trial). Once daily dosing. Start low (1.25 mg) in HF and titrate to target 10 mg. Hydrophilic - minimal CNS effects (less depression/nightmares than propranolol). Eliminated 50% renal/50% hepatic.'
            },
            nitroglycerin: {
                category: 'Vasodilator<br>Nitrate',
                name: 'Nitroglycerin',
                symbol: 'NTG',
                receptor: 'NO',
                dose: 'Adult: 5-200 Œºg/min IV<br>SL: 0.3-0.6 mg<br>Peds: 0.25-5 Œºg/kg/min',
                class: 'nitroglycerin',
                mechanism: 'NO donor ‚Üí smooth muscle relaxation. Primarily venodilator at low doses (decreases preload), arteriolar dilator at high doses (decreases afterload). Dilates coronary arteries. Decreases myocardial O‚ÇÇ demand.',
                indications: 'Acute coronary syndrome, acute pulmonary edema, hypertensive emergency, heart failure, coronary vasospasm (Prinzmetal angina).',
                contraindications: 'Hypotension (SBP <90), RV infarction, severe aortic stenosis, increased ICP, recent PDE-5 inhibitor use (sildenafil, tadalafil - within 24-48h).',
                sideeffects: 'Hypotension, reflex tachycardia, headache, methemoglobinemia (high doses), tolerance (develops rapidly), syncope.',
                remarks: 'VENODILATOR at low doses (reduces preload) ‚Üí good for pulmonary edema. AVOID in RV infarction (preload-dependent). Tolerance develops within 24-48h of continuous use - nitrate-free intervals needed. DANGEROUS interaction with PDE-5 inhibitors (Viagra) - can cause severe hypotension. Requires special non-PVC tubing. Use glass bottles. Headache very common (cerebral vasodilation).'
            },
            nitroprusside: {
                category: 'Vasodilator<br>Nitrate',
                name: 'Nitroprusside',
                symbol: 'NTP',
                receptor: 'NO',
                dose: 'Adult: 0.25-10 Œºg/kg/min<br>Peds: 0.5-8 Œºg/kg/min',
                class: 'nitroprusside',
                mechanism: 'Direct NO donor ‚Üí smooth muscle relaxation. Balanced arterial AND venous dilation (afterload + preload reduction). Immediate onset, ultra-short duration. Metabolized to cyanide then thiocyanate.',
                indications: 'Hypertensive emergency, acute aortic dissection (with Œ≤-blocker), acute heart failure, controlled hypotension during surgery, acute mitral/aortic regurgitation.',
                contraindications: 'Compensatory hypertension (aortic coarctation, AV shunt), severe renal/hepatic impairment, Leber optic atrophy, tobacco amblyopia, vitamin B12 deficiency.',
                sideeffects: 'Hypotension, cyanide toxicity (prolonged use >48h, high doses, renal failure), thiocyanate toxicity, increased ICP, methemoglobinemia, reflex tachycardia.',
                remarks: 'MOST POTENT vasodilator - immediate onset and offset. Risk of CYANIDE TOXICITY with prolonged use (>48-72h) or high doses (>2 Œºg/kg/min). Monitor thiocyanate levels if >48h use. Signs of toxicity: metabolic acidosis, altered mental status, seizures. Treatment: sodium thiosulfate, hydroxocobalamin. Light-sensitive - protect from light. MUST use with Œ≤-blocker in aortic dissection (prevents reflex tachycardia and increased dP/dt).'
            },
            hydralazine: {
                category: 'Vasodilator<br>Arteriolar dilator',
                name: 'Hydralazine',
                symbol: 'Hydra',
                receptor: 'Direct',
                dose: 'Adult IV: 10-20 mg q4-6h<br>PO: 25-100 mg QID<br>Peds: 0.1-0.2 mg/kg/dose IV',
                class: 'hydralazine',
                mechanism: 'Direct arteriolar vasodilator (afterload reduction). Mechanism unclear - possibly K‚Å∫ channel opening, decreased Ca¬≤‚Å∫ release. Causes reflex tachycardia and increased CO. No venodilation.',
                indications: 'Hypertensive emergency (especially pregnancy), heart failure (with nitrates - BiDil), hypertension, aortic/mitral regurgitation.',
                contraindications: 'Coronary artery disease (reflex tachycardia), mitral valve disease with tachycardia, dissecting aortic aneurysm.',
                sideeffects: 'Reflex tachycardia, headache, flushing, fluid retention, lupus-like syndrome (chronic use >200 mg/day), angina, hypotension.',
                remarks: 'SAFE in pregnancy (first-line for preeclampsia/eclampsia). Causes significant reflex tachycardia - may worsen angina. Used with nitrates in HF (especially in African Americans - A-HeFT trial). Drug-induced lupus with chronic high-dose use (>200 mg/day) - reversible. Often combined with Œ≤-blocker to prevent tachycardia.'
            },
            nicardipine: {
                category: 'Vasodilator<br>CCB - DHP',
                name: 'Nicardipine',
                symbol: 'Nicar',
                receptor: 'Ca++',
                dose: 'Adult: 5-15 mg/h IV<br>Peds: 0.5-3 Œºg/kg/min',
                class: 'nicardipine',
                mechanism: 'Dihydropyridine calcium channel blocker. Blocks L-type Ca¬≤‚Å∫ channels in vascular smooth muscle ‚Üí arterial vasodilation. Minimal cardiac effects (vascular selective). Cerebral vasodilator.',
                indications: 'Hypertensive emergency, perioperative hypertension, subarachnoid hemorrhage (prevent vasospasm), acute ischemic stroke with severe hypertension.',
                contraindications: 'Advanced aortic stenosis, acute MI, severe hypotension.',
                sideeffects: 'Hypotension, reflex tachycardia, headache, flushing, peripheral edema, phlebitis (peripheral IV).',
                remarks: 'EXCELLENT for acute BP control - predictable, titratable. PREFERRED over nitroprusside (no cyanide toxicity). Cerebral vasodilator - may increase ICP but maintains cerebral perfusion. SAFE in pregnancy. Reflex tachycardia less than hydralazine. Can cause phlebitis - central line preferred. Does NOT worsen coronary steal (unlike older CCBs).'
            },
            enalapril: {
                category: 'ACE Inhibitor<br>Prodrug',
                name: 'Enalapril',
                symbol: 'Enal',
                receptor: 'ACEi',
                dose: 'Adult IV: 0.625-1.25 mg q6h<br>PO: 2.5-40 mg daily<br>Peds: 0.05-0.1 mg/kg/day',
                class: 'enalapril',
                mechanism: 'ACE inhibitor - blocks conversion of angiotensin I ‚Üí II. Decreases SVR, aldosterone, sympathetic activity. Increases bradykinin (cough). Reduces afterload and preload.',
                indications: 'Heart failure, hypertension, post-MI LV dysfunction, diabetic nephropathy, chronic kidney disease.',
                contraindications: 'Pregnancy (teratogenic), bilateral renal artery stenosis, angioedema history, hyperkalemia.',
                sideeffects: 'Hypotension (especially first dose), hyperkalemia, acute kidney injury, cough (10-20%), angioedema (0.1-0.2%), rash.',
                remarks: 'Mortality benefit in HF and post-MI. First-dose hypotension common - start low. Monitor K‚Å∫ and creatinine. Cough due to bradykinin accumulation (switch to ARB if intolerable). AVOID in pregnancy (fetal renal dysgenesis). Risk of angioedema - more common in African Americans. Enalaprilat is IV form (only IV ACE inhibitor available).'
            },
            lisinopril: {
                category: 'ACE Inhibitor<br>Active form',
                name: 'Lisinopril',
                symbol: 'Lisin',
                receptor: 'ACEi',
                dose: 'Adult: 2.5-40 mg daily<br>Peds: 0.07-0.6 mg/kg/day',
                class: 'lisinopril',
                mechanism: 'ACE inhibitor - active form (not prodrug). Blocks angiotensin I ‚Üí II conversion. Long half-life allows once-daily dosing. Hydrophilic - minimal CNS penetration.',
                indications: 'Heart failure, hypertension, post-MI, diabetic nephropathy, chronic kidney disease.',
                contraindications: 'Pregnancy, bilateral RAS, angioedema history, hyperkalemia.',
                sideeffects: 'Hypotension, hyperkalemia, AKI, cough, angioedema, dizziness.',
                remarks: 'NOT a prodrug - active form. Once daily dosing. Hydrophilic - eliminated unchanged by kidneys (dose adjust in renal impairment). NO IV formulation. Same benefits as other ACE inhibitors. Start low in HF (2.5 mg) and titrate to target dose (20-40 mg).'
            },
            ramipril: {
                category: 'ACE Inhibitor<br>Prodrug',
                name: 'Ramipril',
                symbol: 'Rami',
                receptor: 'ACEi',
                dose: 'Adult: 1.25-10 mg daily<br>Peds: Limited data',
                class: 'ramipril',
                mechanism: 'ACE inhibitor prodrug ‚Üí ramiprilat (active). Long-acting. Tissue ACE inhibition. Reduces cardiovascular events.',
                indications: 'Heart failure, post-MI, hypertension, high CV risk (HOPE trial), diabetic nephropathy.',
                contraindications: 'Pregnancy, bilateral RAS, angioedema history.',
                sideeffects: 'Hypotension, hyperkalemia, AKI, cough, angioedema.',
                remarks: 'Proven CV risk reduction in HOPE trial. High tissue penetration. Once daily dosing. Prodrug - converted to active ramiprilat. Similar efficacy to other ACE inhibitors for HF and post-MI.'
            },
            amiodarone: {
                category: 'Antiarrhythmic<br>Class III',
                name: 'Amiodarone',
                symbol: 'Amio',
                receptor: 'K+',
                dose: 'Adult Load: 150 mg IV over 10min, then 1 mg/min √ó 6h, then 0.5 mg/min<br>PO: 400-800 mg/day √ó 1-3wk, then 200-400 mg/day<br>Peds: 5 mg/kg IV',
                class: 'amiodarone',
                mechanism: 'Class III antiarrhythmic - primarily K‚Å∫ channel blocker (prolongs repolarization/QT). Also blocks Na‚Å∫, Ca¬≤‚Å∫ channels, Œ±/Œ≤ receptors. Multiple mechanisms. Non-competitive Œ≤-blocker effect.',
                indications: 'Ventricular tachycardia/fibrillation, atrial fibrillation (rate/rhythm control), cardiac arrest (VF/pVT), SVT refractory to other agents.',
                contraindications: 'Sinus bradycardia, 2nd/3rd degree AV block (without pacemaker), long QT syndrome, iodine allergy (relative).',
                sideeffects: 'QT prolongation, torsades, bradycardia, hypotension (IV), pulmonary toxicity, hepatotoxicity, thyroid dysfunction (hypo/hyper), corneal deposits, photosensitivity, blue-gray skin discoloration.',
                remarks: 'MOST EFFECTIVE antiarrhythmic but MOST TOXIC. IV causes hypotension (due to solvent polysorbate 80). Use central line for prolonged infusion (causes phlebitis). Very long half-life (20-100 days) - effects persist weeks after stopping. Pulmonary toxicity most serious (interstitial pneumonitis/fibrosis) - monitor PFTs, CXR. Check thyroid function (contains iodine - 37% by weight). MANY drug interactions (CYP450 inhibitor). Reduces defibrillation threshold. Preferred in cardiac arrest and structural heart disease.'
            },
            lidocaine: {
                category: 'Antiarrhythmic<br>Class IB',
                name: 'Lidocaine',
                symbol: 'Lido',
                receptor: 'Na+',
                dose: 'Adult: 1-1.5 mg/kg bolus, then 1-4 mg/min<br>Peds: 1 mg/kg bolus, then 20-50 Œºg/kg/min',
                class: 'lidocaine',
                mechanism: 'Class IB antiarrhythmic - Na‚Å∫ channel blocker. Shortens action potential duration. Decreases ventricular automaticity. Minimal effect on atrial tissue.',
                indications: 'Ventricular arrhythmias (VT/VF), especially in acute MI, cardiac arrest (alternative to amiodarone), local anesthesia.',
                contraindications: 'Advanced AV block, severe sinus node dysfunction, Wolff-Parkinson-White syndrome, lidocaine allergy.',
                sideeffects: 'CNS toxicity (paresthesias, confusion, seizures), bradycardia, hypotension, heart block, methemoglobinemia.',
                remarks: 'VENTRICULAR-selective (minimal atrial effects). CNS toxicity dose-related: paresthesias ‚Üí drowsiness ‚Üí seizures ‚Üí coma. Reduce dose in liver disease, HF, elderly (decreased clearance). Monitor levels (therapeutic 1.5-5 Œºg/mL). Amiodarone now preferred over lidocaine in cardiac arrest. Good for VT in acute MI. NO longer recommended for routine prophylaxis post-MI.'
            },
            adenosine: {
                category: 'Antiarrhythmic<br>Nucleoside',
                name: 'Adenosine',
                symbol: 'Adeno',
                receptor: 'A1',
                dose: 'Adult: 6 mg rapid IV push, then 12 mg √ó 2 if needed<br>Peds: 0.1 mg/kg, max 6 mg initial',
                class: 'adenosine',
                mechanism: 'Activates A1 receptors ‚Üí increases K‚Å∫ conductance ‚Üí hyperpolarization. Slows AV conduction. Ultra-short half-life (<10 sec). Causes transient AV block.',
                indications: 'Supraventricular tachycardia (AVNRT, AVRT), wide-complex tachycardia (diagnostic), stress testing (pharmacologic).',
                contraindications: 'Asthma/COPD (bronchospasm), 2nd/3rd degree AV block, sick sinus syndrome, atrial fibrillation/flutter with WPW, recent dipyridamole use.',
                sideeffects: 'Transient asystole, flushing, chest pain/tightness, dyspnea, bronchospasm, sense of "impending doom".',
                remarks: 'ULTRA-SHORT half-life - effects last seconds. Give RAPID IV push followed by saline flush - use large bore IV, as proximal as possible. WARN patient of impending discomfort (chest pain, flushing, dyspnea). Causes brief asystole - have defibrillator ready. May unmask WPW pattern. Bronchospasm risk - avoid in asthma. Caffeine/theophylline antagonize effects (higher doses needed). Dipyridamole potentiates effects (contraindicated within 24h). NOT effective for atrial fib/flutter (may cause transient AV block revealing flutter waves). Record ECG during administration.'
            },
            procainamide: {
                category: 'Antiarrhythmic<br>Class IA',
                name: 'Procainamide',
                symbol: 'Proc',
                receptor: 'Na+',
                dose: 'Adult: 15-18 mg/kg IV over 30-60min, then 1-4 mg/min<br>Peds: 15 mg/kg IV load',
                class: 'procainamide',
                mechanism: 'Class IA - Na‚Å∫ channel blocker + K‚Å∫ channel blocker. Slows conduction, prolongs repolarization. Active metabolite NAPA also antiarrhythmic.',
                indications: 'Ventricular tachycardia, atrial fibrillation (especially with WPW), SVT, pre-excitation syndromes.',
                contraindications: 'Torsades de pointes, long QT, SLE, complete AV block, myasthenia gravis.',
                sideeffects: 'Hypotension, QT prolongation, torsades, drug-induced lupus (50-90% with chronic use), agranulocytosis, heart block, QRS widening.',
                remarks: 'RARELY used chronically due to lupus (50-90% develop lupus antibodies). Monitor BP during infusion (can cause severe hypotension - slow infusion). Watch QRS width (stop if >50% increase) and QT interval. Check ANA levels periodically. Good for WPW with AF (amiodarone may paradoxically increase conduction through accessory pathway). NAPA metabolite accumulates in renal failure.'
            },
            sotalol: {
                category: 'Antiarrhythmic<br>Class III + Œ≤-blocker',
                name: 'Sotalol',
                symbol: 'Sota',
                receptor: 'K+, Œ≤',
                dose: 'Adult: 80-160 mg BID PO<br>Peds: 30-90 mg/m¬≤/dose',
                class: 'sotalol',
                mechanism: 'Dual mechanism: Class III (K‚Å∫ channel blocker - prolongs QT) + non-selective Œ≤-blocker. Prolongs repolarization and decreases HR.',
                indications: 'Ventricular arrhythmias, atrial fibrillation (rhythm control), life-threatening arrhythmias.',
                contraindications: 'Long QT syndrome, torsades, severe renal impairment (accumulates), asthma, bradycardia, decompensated HF, hypokalemia.',
                sideeffects: 'Torsades de pointes (dose-related), bradycardia, heart failure, bronchospasm, fatigue, QT prolongation.',
                remarks: 'PROARRHYTHMIC - torsades risk 2-4% (dose-dependent). MUST initiate in hospital with continuous monitoring (first 3 days). Check QTc before each dose increase - hold if QTc >500 ms. Renally excreted - dose adjust for CrCl. Correct hypokalemia before starting. More effective than other antiarrhythmics but higher torsades risk. Combines benefits of Œ≤-blocker and Class III agent.'
            },
            furosemide: {
                category: 'Diuretic<br>Loop diuretic',
                name: 'Furosemide',
                symbol: 'Lasix',
                receptor: 'Na/K/2Cl',
                dose: 'Adult: 20-80 mg IV/PO, max 600 mg/day<br>Infusion: 5-40 mg/h<br>Peds: 0.5-2 mg/kg/dose',
                class: 'furosemide',
                mechanism: 'Loop diuretic - inhibits Na‚Å∫-K‚Å∫-2Cl‚Åª cotransporter in thick ascending limb of Henle. Venodilation (rapid - before diuresis). Decreases preload, pulmonary congestion.',
                indications: 'Acute pulmonary edema, heart failure exacerbation, volume overload, hypertension, hypercalcemia, acute kidney injury (controversial).',
                contraindications: 'Anuria, severe electrolyte depletion, hepatic coma, sulfa allergy.',
                sideeffects: 'Hypokalemia, hypomagnesemia, hypocalcemia, metabolic alkalosis, ototoxicity (high doses), hyperuricemia, hyperglycemia, hypovolemia, hyponatremia.',
                remarks: 'MOST commonly used loop diuretic. IV administration causes immediate venodilation (reduces preload before diuresis starts). Ceiling effect - doubling dose doesn\'t double response; use continuous infusion if resistant. Ototoxicity with high doses/rapid infusion - risk with aminoglycosides. Monitor electrolytes (especially K‚Å∫, Mg¬≤‚Å∫). Poor absorption in gut edema - IV preferred in acute HF. May need to add thiazide (metolazone) for diuretic resistance. AVOID in hypovolemic states.'
            },
            bumetanide: {
                category: 'Diuretic<br>Loop diuretic',
                name: 'Bumetanide',
                symbol: 'Bumex',
                receptor: 'Na/K/2Cl',
                dose: 'Adult: 0.5-2 mg IV/PO<br>Peds: 0.015-0.1 mg/kg/dose',
                class: 'bumetanide',
                mechanism: 'Loop diuretic - Na‚Å∫-K‚Å∫-2Cl‚Åª cotransporter inhibitor. More potent than furosemide (40:1 ratio). Better bioavailability.',
                indications: 'Heart failure, edema, furosemide resistance, hypertension.',
                contraindications: 'Anuria, severe electrolyte depletion, sulfa allergy, hepatic coma.',
                sideeffects: 'Similar to furosemide: hypokalemia, metabolic alkalosis, ototoxicity (less than furosemide), hyperuricemia.',
                remarks: '40√ó more potent than furosemide (1 mg bumetanide ‚âà 40 mg furosemide). Better oral bioavailability (80-90% vs 50% for furosemide) - more reliable PO dosing. LESS ototoxic than furosemide. Useful when switching from IV to PO due to predictable absorption. Shorter duration than furosemide. Consider when furosemide resistance develops.'
            },
            torsemide: {
                category: 'Diuretic<br>Loop diuretic',
                name: 'Torsemide',
                symbol: 'Torsem',
                receptor: 'Na/K/2Cl',
                dose: 'Adult: 10-20 mg IV/PO daily<br>Peds: Limited data',
                class: 'torsemide',
                mechanism: 'Loop diuretic - Na‚Å∫-K‚Å∫-2Cl‚Åª cotransporter inhibitor. Longer half-life (3-4h vs 1.5h for furosemide). Additional aldosterone antagonist effects.',
                indications: 'Heart failure (especially chronic), hypertension, edema, cirrhotic ascites.',
                contraindications: 'Anuria, severe electrolyte depletion, sulfa allergy.',
                sideeffects: 'Hypokalemia, metabolic alkalosis, hyperuricemia, ototoxicity (rare).',
                remarks: 'BEST oral bioavailability (80-90%) - reliable PO dosing. Longer duration allows once-daily dosing. May be superior to furosemide in chronic HF (TRANSFORM-HF trial - neutral results). Less ototoxic than furosemide. 1 mg torsemide ‚âà 2 mg bumetanide ‚âà 40 mg furosemide. Some aldosterone antagonist effect. Useful for chronic HF management.'
            },
            spironolactone: {
                category: 'Diuretic<br>K‚Å∫-sparing MRA',
                name: 'Spironolactone',
                symbol: 'Spir',
                receptor: 'MRA',
                dose: 'Adult: 12.5-50 mg daily<br>Peds: 1-3 mg/kg/day',
                class: 'spironolactone',
                mechanism: 'Mineralocorticoid receptor antagonist (MRA) - blocks aldosterone in distal tubule. Weak diuretic but potent mortality benefit in HF. Anti-fibrotic, anti-remodeling effects.',
                indications: 'Heart failure with reduced EF (mortality benefit), resistant hypertension, primary hyperaldosteronism, cirrhotic ascites.',
                contraindications: 'Hyperkalemia (K‚Å∫ >5.5), severe renal failure (CrCl <30), Addison disease, concurrent K‚Å∫-sparing diuretics.',
                sideeffects: 'Hyperkalemia (LIFE-THREATENING), gynecomastia (20% men), menstrual irregularities, GI upset, hyponatremia.',
                remarks: 'MORTALITY BENEFIT in HF (RALES trial - 30% mortality reduction). Start LOW dose (12.5-25 mg) and monitor K‚Å∫ closely (weekly √ó 1 month, then monthly). DANGEROUS hyperkalemia risk - avoid with K‚Å∫ >5, CrCl <30, or ACE-I/ARB + NSAIDs. Gynecomastia common (non-selective MRA) - switch to eplerenone if bothersome. Anti-fibrotic effects independent of diuresis. Essential in HF with EF <35%.'
            },
            eplerenone: {
                category: 'Diuretic<br>K‚Å∫-sparing MRA',
                name: 'Eplerenone',
                symbol: 'Epler',
                receptor: 'MRA',
                dose: 'Adult: 25-50 mg daily<br>Peds: Limited data',
                class: 'eplerenone',
                mechanism: 'Selective mineralocorticoid receptor antagonist. More selective than spironolactone (less anti-androgen effects). Blocks aldosterone, reduces cardiac fibrosis.',
                indications: 'Heart failure post-MI, HFrEF, hypertension.',
                contraindications: 'Hyperkalemia, severe renal impairment, concurrent strong CYP3A4 inhibitors.',
                sideeffects: 'Hyperkalemia, hyponatremia, dizziness. LESS gynecomastia than spironolactone.',
                remarks: 'SELECTIVE MRA - much less gynecomastia than spironolactone. Mortality benefit post-MI (EPHESUS trial). Monitor K‚Å∫ closely. More expensive than spironolactone. Preferred when gynecomastia is issue. CYP3A4 interactions - avoid with ketoconazole, itraconazole.'
            },
            heparin: {
                category: 'Anticoagulant<br>Unfractionated',
                name: 'Heparin (UFH)',
                symbol: 'UFH',
                receptor: 'ATIII',
                dose: 'Adult: 60-80 U/kg bolus, then 12-18 U/kg/h<br>Peds: 75 U/kg bolus, then 20 U/kg/h',
                class: 'heparin',
                mechanism: 'Binds antithrombin III ‚Üí inactivates thrombin (IIa) and factor Xa. Immediate anticoagulation. Monitored by aPTT (target 1.5-2.5√ó control).',
                indications: 'ACS, PE/DVT, atrial fibrillation, mechanical valves, ECMO/CVVH, cardiopulmonary bypass.',
                contraindications: 'Active bleeding, severe thrombocytopenia, HIT (heparin-induced thrombocytopenia).',
                sideeffects: 'Bleeding, HIT (0.1-5%), osteoporosis (long-term), hyperkalemia, alopecia.',
                remarks: 'IMMEDIATE anticoagulation - preferred when rapid reversal may be needed (protamine). Monitor aPTT (target 60-80 sec or 1.5-2.5√ó baseline). HIT risk - monitor platelets (especially days 5-14). Protamine reverses (1 mg per 100 U heparin). Preferred over LMWH in renal failure, extreme obesity, when rapid on/off needed (pre-procedure).'
            },
            enoxaparin: {
                category: 'Anticoagulant<br>LMWH',
                name: 'Enoxaparin',
                symbol: 'LMWH',
                receptor: 'Xa > IIa',
                dose: 'Adult: 1 mg/kg q12h or 1.5 mg/kg daily<br>Peds: 1 mg/kg q12h',
                class: 'enoxaparin',
                mechanism: 'Low molecular weight heparin - preferentially inhibits factor Xa > IIa. More predictable than UFH. Longer half-life.',
                indications: 'ACS, PE/DVT treatment/prophylaxis, bridging anticoagulation.',
                contraindications: 'Severe renal impairment (CrCl <30), active bleeding, HIT.',
                sideeffects: 'Bleeding, HIT (lower risk than UFH), spinal hematoma (avoid with neuraxial procedures), osteoporosis.',
                remarks: 'MORE predictable than UFH - usually no monitoring needed. Avoid in severe renal failure (accumulates - dose reduce if CrCl 30-50). LOWER HIT risk than UFH. Partially reversed by protamine (60-80%). Contraindicated within 12h of neuraxial anesthesia/catheter manipulation. Preferred over UFH for outpatient DVT/PE treatment.'
            },
            warfarin: {
                category: 'Anticoagulant<br>Vitamin K antagonist',
                name: 'Warfarin',
                symbol: 'Warf',
                receptor: 'Vit. K',
                dose: 'Adult: 2-10 mg daily (titrate to INR)<br>Peds: 0.1-0.3 mg/kg/day',
                class: 'warfarin',
                mechanism: 'Vitamin K antagonist - inhibits factors II, VII, IX, X and proteins C, S. Monitored by INR (target varies by indication: 2-3 for most, 2.5-3.5 for mechanical valves).',
                indications: 'Atrial fibrillation, mechanical heart valves, DVT/PE, left ventricular thrombus.',
                contraindications: 'Pregnancy (teratogenic), active bleeding, inability to monitor INR, recent CNS surgery.',
                sideeffects: 'Bleeding, skin necrosis (proteins C/S deficiency), warfarin-induced limb gangrene, teratogenicity.',
                remarks: 'NARROW therapeutic window - frequent INR monitoring required. MANY drug and food interactions. Teratogenic - avoid in pregnancy (especially 1st trimester). Bridging with heparin needed (initial paradoxical hypercoagulability from protein C/S inhibition). Reversed by vitamin K (slow, 6-24h) or PCC/FFP (immediate). DOACs replacing warfarin for many indications except mechanical valves.'
            },
            apixaban: {
                category: 'Anticoagulant<br>DOAC - Xa inhibitor',
                name: 'Apixaban',
                symbol: 'Apix',
                receptor: 'Xa-i',
                dose: 'Adult: 5 mg BID (AF), 2.5 mg BID if ‚â•2: age‚â•80, wt‚â§60kg, Cr‚â•1.5<br>DVT: 10 mg BID √ó 7d, then 5 mg BID',
                class: 'apixaban',
                mechanism: 'Direct oral anticoagulant (DOAC) - direct factor Xa inhibitor. Predictable pharmacokinetics. No routine monitoring needed.',
                indications: 'Atrial fibrillation (stroke prevention), DVT/PE treatment and prophylaxis.',
                contraindications: 'Active bleeding, severe hepatic impairment, mechanical valves, severe renal impairment (CrCl <15).',
                sideeffects: 'Bleeding (lower than warfarin), GI upset. No reversal agent widely available (andexanet alfa).',
                remarks: 'LOWEST bleeding risk among DOACs (especially intracranial). BID dosing (adherence concern). Dose reduce if ‚â•2 criteria: age‚â•80, weight‚â§60kg, Cr‚â•1.5. NO routine monitoring needed. Reversal: andexanet alfa (expensive, limited availability). Preferred over warfarin in many patients (ARISTOTLE trial). NOT for mechanical valves (increased thromboembolic events).'
            }
        };

        const table = document.getElementById('pharmaTable');
        const tooltip = document.getElementById('tooltip');

        // Define drug order
        const drugOrder = [
            // Row 1: Vasopressors
            'norepinephrine', 'epinephrine', 'vasopressin', 'phenylephrine', 'dopamine', 'terlipressin',
            // Row 2: Inotropes
            'dobutamine', 'milrinone', 'levosimendan', 'digoxin', 'isoproterenol',
            // Row 3: Beta-blockers (need one more to complete)
            'metoprolol', 'esmolol', 'propranolol', 'carvedilol', 'labetalol', 'bisoprolol',
            // Row 4: Vasodilators + ACE inhibitors
            'nitroglycerin', 'nitroprusside', 'hydralazine', 'nicardipine', 'enalapril', 'lisinopril',
            // Row 5: ACE + Antiarrhythmics
            'ramipril', 'amiodarone', 'lidocaine', 'adenosine', 'procainamide', 'sotalol',
            // Row 6: Diuretics + Anticoagulants
            'furosemide', 'bumetanide', 'torsemide', 'spironolactone', 'eplerenone', 'heparin',
            // Row 7: Anticoagulants
            'enoxaparin', 'warfarin', 'apixaban'
        ];

        drugOrder.forEach(drugId => {
            const drug = drugs[drugId];
            if (drug) {
                const element = document.createElement('div');
                element.className = `card ${drug.class}`;
                element.innerHTML = `
                    <div class="card-category">${drug.category}</div>
                    <div class="card-receptor">${drug.receptor || ''}</div>
                    <div class="card-name">${drug.symbol || drug.name}</div>
                    <div class="card-dose">${drug.dose}</div>
                `;
                
                element.addEventListener('mouseenter', (e) => showTooltip(e, drug));
                element.addEventListener('mousemove', (e) => updateTooltipPosition(e));
                element.addEventListener('mouseleave', hideTooltip);
                
                table.appendChild(element);
            }
        });

        function showTooltip(e, drug) {
            const color = window.getComputedStyle(e.currentTarget).color;
            const borderColor = window.getComputedStyle(e.currentTarget).borderColor;
            
            tooltip.style.color = color;
            tooltip.style.borderColor = borderColor;
            
            tooltip.innerHTML = `
                <div class="tooltip-title">${drug.name}</div>
                <div class="tooltip-section">
                    <div class="tooltip-section-title">Mechanism of Action</div>
                    <div class="tooltip-section-content">${drug.mechanism}</div>
                </div>
                <div class="tooltip-section">
                    <div class="tooltip-section-title">Indications</div>
                    <div class="tooltip-section-content">${drug.indications}</div>
                </div>
                <div class="tooltip-section">
                    <div class="tooltip-section-title">Contraindications</div>
                    <div class="tooltip-section-content">${drug.contraindications}</div>
                </div>
                <div class="tooltip-section">
                    <div class="tooltip-section-title">Side Effects</div>
                    <div class="tooltip-section-content">${drug.sideeffects}</div>
                </div>
                <div class="tooltip-section">
                    <div class="tooltip-section-title">Clinical Pearls & Remarks</div>
                    <div class="tooltip-section-content">${drug.remarks}</div>
                </div>
            `;
            
            updateTooltipPosition(e);
            tooltip.classList.add('active');
        }

        function updateTooltipPosition(e) {
            const margin = 20;
            let x = e.clientX + margin;
            let y = e.clientY + margin;
            
            const tooltipRect = tooltip.getBoundingClientRect();
            
            if (x + tooltipRect.width > window.innerWidth - margin) {
                x = e.clientX - tooltipRect.width - margin;
            }
            
            if (y + tooltipRect.height > window.innerHeight - margin) {
                y = e.clientY - tooltipRect.height - margin;
            }
            
=======
        const drugs = [
    // === VASOPRESSORS & INOPRESSORS ===
    { 
        s: "Ne", n: "Norepinephrine", cat: "v", trade: "Levophed", grp: "Pressor", sub: "Œ±1 > Œ≤1", 
        ad: "0.01-1.0 ¬µg/kg/min", ch: "0.05-0.1 ¬µg/kg/min",
        mech: "Potent Œ±1-adrenergic agonist (vasoconstriction) with moderate Œ≤1 activity (inotropy). Increases SVR and MAP primarily through arterial and venous constriction. Œ≤1 effects provide mild inotropic support. Minimal effect on HR at therapeutic doses.",
        indications: "First-line vasopressor for septic shock, distributive shock states, cardiogenic shock with low SVR, neurogenic shock, anaphylaxis.",
        contraindications: "Hypovolemia without adequate fluid resuscitation (relative). Avoid in pheochromocytoma.",
        sideeffects: "Tissue necrosis if extravasation, reflex bradycardia, arrhythmias, digital ischemia at high doses.",
        picco: "GOLD STANDARD vasopressor. Monitor SVRI - expect significant increase. Target MAP ‚â•65 mmHg. May decrease CI initially if severe vasoconstriction.",
        rem: "Surviving Sepsis Guidelines: FIRST-LINE agent. More predictable than dopamine with LOWER arrhythmia risk. Do NOT mix with alkaline solutions."
    },
    { 
        s: "Ad", n: "Epinephrine", cat: "v", trade: "Adrenaline", grp: "Inopressor", sub: "Œ±/Œ≤ agonist", 
        ad: "0.01-0.5 ¬µg/kg/min", ch: "0.1-1.0 ¬µg/kg/min",
        mech: "Non-selective Œ± and Œ≤ adrenergic agonist. LOW doses (<0.05): predominantly Œ≤1/Œ≤2 (inotropy). HIGH doses: Œ±1 predominates (vasoconstriction). Increases CO, HR, and SVR.",
        indications: "Anaphylaxis, cardiac arrest, severe bradycardia, refractory shock, post-cardiac surgery low output state.",
        contraindications: "No absolute in emergencies. Relative: uncontrolled tachyarrhythmias, hypertrophic cardiomyopathy.",
        sideeffects: "Highly arrhythmogenic, severe tachycardia, hyperglycemia, type B lactic acidosis (Œ≤2-mediated).",
        picco: "Expect dramatic increase in CI and CO. HR often increases significantly. SVRI varies by dose. Causes paradoxically high lactate - check ScvO2.",
        rem: "Extreme caution - most arrhythmogenic catecholamine. First-line for anaphylaxis (IM route). AVOID in cocaine-induced chest pain."
    },
    {
        s: "Vp", n: "Vasopressin", cat: "v", trade: "Empressin", grp: "Pressor", sub: "V1 agonist",
        ad: "0.01-0.04 U/min", ch: "0.0003-0.002 U/kg/min",
        mech: "V1 receptor agonist causing vascular smooth muscle contraction. Non-adrenergic. Maintains tone in catecholamine-refractory shock by restoring vascular responsiveness.",
        indications: "Adjunct to norepinephrine in septic shock, vasodilatory shock post-bypass, cardiac arrest (single 40U dose).",
        contraindications: "Relative: CAD, peripheral vascular disease. Fixed dose only (0.03-0.04 U/min).",
        sideeffects: "Digital/splanchnic ischemia, hyponatremia (V2 effect), coronary vasoconstriction, decreased CO.",
        picco: "Expect SVRI increase without change in HR. CI may DECREASE due to increased afterload - monitor carefully.",
        rem: "ALWAYS use as ADJUNCT to norepinephrine. FIXED DOSE - do not titrate. VASST trial: benefit in less severe septic shock."
    },

    // === INOTROPES & INODILATORS ===
    {
        s: "Db", n: "Dobutamine", cat: "i", trade: "Dobutrex", grp: "Inotrope", sub: "Œ≤1 agonist",
        ad: "2-20 ¬µg/kg/min", ch: "2-20 ¬µg/kg/min",
        mech: "Direct Œ≤1 agonist. Increases contractility and heart rate. Mild Œ≤2 and Œ±1 effects. Overall net effect is increased CO with decreased/neutral SVR.",
        indications: "Cardiogenic shock, low output heart failure, sepsis with myocardial depression, stress echocardiography.",
        contraindications: "HOCM with obstruction, suspected pheochromocytoma, severe aortic stenosis.",
        sideeffects: "Tachycardia, ventricular arrhythmias, hypotension (Œ≤2 effect), increased myocardial oxygen demand.",
        picco: "Primary indicator: improvement in CI and GEF/CFI. Watch for 'Inodilator' effect (lowering SVRI). If MAP drops too much, add Norepinephrine.",
        rem: "Short half-life (2 mins). Tachyphylaxis may occur after 72h. Preferred in heart failure due to less effect on HR than Isoprenaline."
    },
    {
        s: "Ls", n: "Levosimendan", cat: "i", trade: "Simdax", grp: "Inodilator", sub: "Ca-sensitizer",
        ad: "0.05-0.2 ¬µg/kg/min", ch: "N/A (Limited data)",
        mech: "Sensitizes troponin C to calcium (inotropy) and opens ATP-sensitive K-channels (vasodilation). Does NOT increase intracellular calcium or O2 demand.",
        indications: "Acute decompensated HF where conventional inotropes fail, right heart failure, cardiac surgery weaning.",
        contraindications: "Severe hypotension, severe renal/hepatic impairment, history of Torsades de Pointes.",
        sideeffects: "Hypotension, headache, hypokalemia, atrial fibrillation.",
        picco: "Monitor GEF/CFI for contractility improvement. Note long-lasting effect: metabolite active for 7-10 days. Check SVRI (significant drop expected).",
        rem: "Usually given as 24-hour infusion. Does not increase O2 demand, making it safer in ischemic cardiomyopathy."
    },
    {
        s: "Mi", n: "Milrinone", cat: "i", trade: "Primacor", grp: "Inodilator", sub: "PDE3 inhibitor",
        ad: "0.375-0.75 ¬µg/kg/min", ch: "0.25-0.75 ¬µg/kg/min",
        mech: "Phosphodiesterase-3 inhibitor. Increases cAMP ‚Üí inotropy in heart & vasodilation in vessels. Potent pulmonary vasodilator.",
        indications: "Acute heart failure, pulmonary hypertension, low CO after cardiac surgery, bridge to transplant.",
        contraindications: "Severe obstructive valvular disease, acute MI, severe hypotension.",
        sideeffects: "Hypotension (venous and arterial), ventricular arrhythmias, thrombocytopenia (rare), headache.",
        picco: "Excellent for right-sided failure. Expect CI increase and SVRI decrease. Monitor ELWI - if EVLW is high, Milrinone helps unloading.",
        rem: "Renally cleared (reduce dose if GFR <30). Does not rely on Œ≤-receptors, so effective in patients on chronic Œ≤-blockers."
    },

    // === SEDATIVES & RELAXANTS ===
    { 
        s: "Pf", n: "Propofol", cat: "s", trade: "Diprivan", grp: "Sedative", sub: "GABA-A agonist", 
        ad: "0.5-4.0 mg/kg/hr", ch: "1.0-3.0 mg/kg/hr",
        mech: "Global CNS depression via GABA-A receptor agonism. Decreases cerebral metabolic rate (CMRO2) and ICP. Has anti-convulsant and anti-emetic properties.",
        indications: "Induction and maintenance of general anesthesia, ICU sedation, procedural sedation.",
        contraindications: "Hypersensitivity to egg/soy. Severe hemodynamic instability.",
        sideeffects: "Hypotension, respiratory depression, PRIS, hypertriglyceridemia.",
        picco: "Expect SVRI decrease. May decrease CI due to negative inotropy. If MAP drops, recalibrate PiCCO after adjusting doses.",
        rem: "Rapid onset/offset. PRIS risk: monitor CK and Lactate if doses >4mg/kg/hr."
    },
    { 
        s: "Dx", n: "Dexmedetomidine", cat: "s", trade: "Precedex", grp: "Sedative", sub: "Œ±2 agonist", 
        ad: "0.2-1.4 ¬µg/kg/hr", ch: "0.2-1.0 ¬µg/kg/hr",
        mech: "Selective Œ±2-adrenoceptor agonist in the locus coeruleus. Provides sedation, analgesia, and sympatholysis without significant respiratory depression.",
        indications: "ICU sedation (especially for weaning), delirium management, awake intubation.",
        contraindications: "Advanced heart block, severe bradycardia.",
        sideeffects: "Bradycardia, hypotension (can cause transient hypertension with bolus), dry mouth.",
        picco: "Sympatholytic effect: expect decrease in HR and CI. Usually maintains SVRI but may lower it in hyperdynamic states.",
        rem: "Unique 'cooperative sedation' (patient can be easily aroused). No respiratory depression."
    },
    { 
        s: "Rc", n: "Rocuronium", cat: "r", trade: "Esmeron", grp: "Relaxant", sub: "Non-depol", 
        ad: "0.6-1.0 mg/kg (bolus)", ch: "0.6-1.2 mg/kg",
        mech: "Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction.",
        indications: "Endotracheal intubation, surgical muscle relaxation, mechanical ventilation (shivering/fighting).",
        contraindications: "Hypersensitivity, history of malignant hyperthermia (safe, but use caution).",
        sideeffects: "Tachycardia (mild), prolonged paralysis in liver/renal failure.",
        picco: "Minimal hemodynamic effect. Eliminates patient movement artifacts during TPTD calibration.",
        rem: "Reversal agent: Sugammadex (Bridion) for rapid recovery."
    },

    // === ANTIHYPERTENSIVES & BETA-BLOCKERS ===
    { 
        s: "Bi", n: "Bisoprolol", cat: "b", trade: "Cardiloc", grp: "Œ≤-blocker", sub: "Œ≤1 selective", 
        ad: "1.25-10 mg QD", ch: "0.05-0.1 mg/kg QD",
        mech: "Selective Œ≤1-blockade. Reduces HR and contractility.",
        indications: "CHF, HTN, AF rate control.",
        contraindications: "Acute decompensated HF, heart block, bradycardia.",
        sideeffects: "Bradycardia, hypotension, fatigue.",
        picco: "Expect decrease in CI and HR. Monitor GEF to ensure contractility isn't overly suppressed.",
        rem: "Start low, go slow in CHF."
    },
    { 
        s: "Me", n: "Metoprolol", cat: "b", trade: "Neobloc", grp: "Œ≤-blocker", sub: "Œ≤1 selective", 
        ad: "25-200 mg PO / 5mg IV", ch: "0.1 mg/kg IV",
        mech: "Selective Œ≤1 antagonist. Short-acting (Succinate vs Tartrate).",
        indications: "ACS, tachycardia, HTN.",
        contraindications: "Bradycardia, cardiogenic shock.",
        sideeffects: "Hypotension, cold extremities.",
        picco: "Watch CI. Useful to control tachy-induced low SV in PiCCO analysis.",
        rem: "In Israel: Neobloc (Tartrate) or Lopressor."
    },
    { 
        s: "Nc", n: "Nicardipine", cat: "h", trade: "Cardene", grp: "CCB", sub: "DHP", 
        ad: "5-15 mg/hr IV", ch: "1-3 ¬µg/kg/min",
        mech: "Dihydropyridine calcium channel blocker. Potent arterial vasodilation.",
        indications: "Hypertensive crisis, stroke management.",
        contraindications: "Advanced aortic stenosis.",
        sideeffects: "Reflex tachycardia, headache, flushing.",
        picco: "Expected: Sharp decrease in SVRI, increase in CI (reflex).",
        rem: "Preferred in neuro-emergencies as it doesn't increase ICP."
    },
    { 
        s: "Ur", n: "Urapidil", cat: "h", trade: "Ebrantil", grp: "Vasodilator", sub: "Œ±1 block", 
        ad: "10-50 mg IV", ch: "N/A",
        mech: "Peripheral Œ±1-antagonist and central 5-HT1A receptor agonist.",
        indications: "Hypertensive emergency, aortic dissection.",
        contraindications: "Aortic isthmus stenosis.",
        sideeffects: "Dizziness, nausea.",
        picco: "Reduces afterload (SVRI) without reflex tachycardia. Very stable hemodynamics.",
        rem: "Popular in Europe/Israel for HTN crisis."
    },

    // === DIURETICS & RAAS ===
    { 
        s: "Fu", n: "Furosemide", cat: "d", trade: "Fusid", grp: "Diuretic", sub: "Loop", 
        ad: "20-100 mg IV", ch: "1.0-2.0 mg/kg IV",
        mech: "Inhibits Na-K-Cl symporter in Henle loop.",
        indications: "Edema, CHF, EVLW overload.",
        contraindications: "Anuria, severe hypokalemia.",
        sideeffects: "Hypokalemia, ototoxicity.",
        picco: "Essential for ELWI reduction. Monitor GEDVI to avoid hypovolemia.",
        rem: "PiCCO helps find the 'sweet spot' for diuresis."
    },
    { 
        s: "Ra", n: "Ramipril", cat: "h", trade: "Tritace", grp: "ACEI", sub: "ACE inhibitor", 
        ad: "2.5-10 mg QD", ch: "0.05 mg/kg",
        mech: "Blocks conversion of AT-I to AT-II.",
        indications: "HTN, HF, post-MI.",
        contraindications: "Pregnancy, renal artery stenosis, angioedema.",
        sideeffects: "Dry cough, hyperkalemia.",
        picco: "Long-term afterload reduction (SVRI).",
        rem: "Wait 36h before starting Sacubitril/Valsartan."
    },

    // === ANTIARRHYTHMICS ===
    { 
        s: "Ao", n: "Amiodarone", cat: "a", trade: "Procor", grp: "Class III", sub: "K-blocker", 
        ad: "150-300 mg bolus / 900mg-24h", ch: "5 mg/kg",
        mech: "Blocks K-channels, Na-channels, and has anti-sympathetic activity.",
        indications: "AF, VT, VF.",
        contraindications: "Iodine allergy, heart block.",
        sideeffects: "Bradycardia, liver/thyroid tox.",
        picco: "May decrease CI and HR. Monitor for prolonged QT.",
        rem: "Israel: Procor. Use central line if possible."
    },
    { 
        s: "As", n: "Adenosine", cat: "a", trade: "Adenocor", grp: "Class V", sub: "A1 agonist", 
        ad: "6mg -> 12mg rapid IV", ch: "0.1 mg/kg",
        mech: "Slows AV node conduction.",
        indications: "SVT termination.",
        contraindications: "Asthma (relative), 2/3 degree block.",
        sideeffects: "Chest pain, flushing, brief asystole.",
        picco: "Temporary loss of signal. Do not calibrate during administration.",
        rem: "Rapid flush (20ml saline) mandatory."
    },

    // === COAGULATION ===
    { 
        s: "He", n: "Heparin", cat: "c", trade: "Heparin", grp: "Anticoag", sub: "UFH", 
        ad: "70-100 U/kg bolus", ch: "75 U/kg",
        mech: "Potentiates Antithrombin III.",
        indications: "ACS, PE, DVT, ECMO.",
        contraindications: "Active bleed, HIT.",
        sideeffects: "Bleeding, thrombocytopenia.",
        picco: "No direct hemodynamic effect. Essential for line patency.",
        rem: "Monitor aPTT or ACT."
    },
    { 
        s: "Ex", n: "Enoxaparin", cat: "c", trade: "Clexane", grp: "Anticoag", sub: "LMWH", 
        ad: "1 mg/kg BID", ch: "1 mg/kg BID",
        mech: "Factor Xa inhibitor.",
        indications: "DVT proph/treatment, ACS.",
        contraindications: "Renal failure (CrCl <15).",
        sideeffects: "Bleeding.",
        picco: "Standard in ICU. Monitor renal function.",
        rem: "Standard in Israel (Clexane)."
    },

    // === ADDING MORE (to reach 70+) ===
    { s: "Do", n: "Dopamine", cat: "i", trade: "Dopamine", grp: "Inopressor", sub: "D/Œ≤/Œ± agonist", ad: "2-20 ¬µg/kg/min", ch: "2-20 ¬µg/kg/min", mech: "Dose dependent: Low (D-receptors), Mid (Œ≤1), High (Œ±1).", indications: "Bradycardia, Shock.", contraindications: "Tachyarrhythmias.", sideeffects: "Arrhythmias.", picco: "Watch HR and SVRI. High arrhythmia risk.", rem: "Less used today than Norepi/Dobutamine." },
    { s: "Is", n: "Isoprenaline", cat: "i", trade: "Isuprel", grp: "Inotrope", sub: "Œ≤1/Œ≤2 agonist", ad: "0.5-5 ¬µg/min", ch: "0.1 ¬µg/kg/min", mech: "Pure Œ≤-agonist. Potent chronotrope/inotrope.", indications: "Bradycardia, Heart Block.", contraindications: "Angina, Tachycardia.", sideeffects: "Profound tachycardia.", picco: "Sharp CI/HR increase. SVRI usually drops (Œ≤2).", rem: "Used as bridge to pacing." },
    { s: "Ni", n: "Nitroglycerin", cat: "h", trade: "Nitroderm", grp: "Nitrate", sub: "Venodilator", ad: "5-200 ¬µg/min", ch: "1-5 ¬µg/kg/min", mech: "NO donor. Primarily venodilation (Preload reduction).", indications: "ACS, Heart Failure.", contraindications: "Sildenafil use, Hypotension.", sideeffects: "Headache, hypotension.", picco: "Reduces GEDVI (preload). Helpful in high ELWI cases.", rem: "Tachyphylaxis after 24h." },
    { s: "Hy", n: "Hydralazine", cat: "h", trade: "Apresoline", grp: "Vasodilator", sub: "Arterial", ad: "10-20 mg IV", ch: "0.1-0.5 mg/kg", mech: "Direct arterial vasodilator.", indications: "Pregnancy HTN, Chronic HF.", contraindications: "SLE, Tachycardia.", sideeffects: "Lupus-like syndrome.", picco: "SVRI reduction. May cause reflex tachycardia.", rem: "Safe in pregnancy." },
    { s: "Ph", n: "Phenylephrine", cat: "v", trade: "Neo-Synephrine", grp: "Pressor", sub: "Pure Œ±1", ad: "20-200 ¬µg/min", ch: "0.1-0.5 ¬µg/kg/min", mech: "Selective Œ±1 agonist. Pure vasoconstriction.", indications: "Anesthesia hypotension, Sepsis (rare).", contraindications: "Severe bradycardia.", sideeffects: "Reflex bradycardia.", picco: "SVRI increases, CI often decreases due to reflex bradycardia.", rem: "Good for 'plumbing' issues without heart rate issues." },
    { s: "Mz", n: "Midazolam", cat: "s", trade: "Dormicum", grp: "Sedative", sub: "Benzo", ad: "0.03-0.2 mg/kg/hr", ch: "0.1-0.2 mg/kg/hr", mech: "GABA-A modulator. Anxiolytic, amnestic.", indications: "ICU sedation, Seizures.", contraindications: "Acute narrow-angle glaucoma.", sideeffects: "Respiratory depression, hypotension.", picco: "Mild vasodilation. Accumulates in renal failure.", rem: "Reversal: Flumazenil." },
    { s: "Ke", n: "Ketamine", cat: "s", trade: "Ketalar", grp: "Sedative", sub: "NMDA antag", ad: "0.5-2.0 mg/kg/hr", ch: "1-2 mg/kg/hr", mech: "Dissociative anesthetic. Sympathomimetic.", indications: "Sedation in shock, Status asthmaticus.", contraindications: "Severe HTN, ICP (relative).", sideeffects: "Hallucinations, HTN.", picco: "Maintains CI and MAP. Good for induction in shock.", rem: "Provides analgesia and sedation." },
    { s: "Su", n: "Succinylcholine", cat: "r", trade: "Scoline", grp: "Relaxant", sub: "Depolarizing", ad: "1-1.5 mg/kg", ch: "2 mg/kg", mech: "Depolarizing NMJ block.", indications: "RSI (Rapid Sequence Intubation).", contraindications: "Hyperkalemia, Burns (>24h), Glaucoma.", sideeffects: "Hyperkalemia, Malignant Hyperthermia.", picco: "Brief tachycardia. Transient K+ rise.", rem: "Fastest onset/shortest duration." },
    { s: "At", n: "Atenolol", cat: "b", trade: "Normiten", grp: "Œ≤-blocker", sub: "Œ≤1 selective", ad: "25-100 mg QD", ch: "0.5-1 mg/kg", mech: "Selective Œ≤1 blocker.", indications: "HTN, Angina.", contraindications: "Bradycardia.", sideeffects: "Fatigue.", picco: "Decreases CI/HR.", rem: "Hydrophilic (less CNS side effects)." },
    { s: "Vs", n: "Valsartan", cat: "h", trade: "Vector", grp: "ARB", sub: "AT1 blocker", ad: "80-320 mg QD", ch: "1.3 mg/kg", mech: "Blocks AT1 receptor.", indications: "HTN, CHF.", contraindications: "Pregnancy.", sideeffects: "Hyperkalemia.", picco: "Afterload reduction (SVRI).", rem: "Israel: Vector." },
    { s: "Am", n: "Amlodipine", cat: "h", trade: "Amlow", grp: "CCB", sub: "DHP", ad: "5-10 mg QD", ch: "0.1 mg/kg", mech: "Arterial vasodilator.", indications: "HTN, Angina.", contraindications: "Severe hypotension.", sideeffects: "Peripheral edema.", picco: "Slow reduction in SVRI.", rem: "Israel: Amlow / Norvasc." },
    { s: "Cl", n: "Clopidogrel", cat: "c", trade: "Plavix", grp: "Antiplatelet", sub: "P2Y12 block", ad: "75 mg QD", ch: "1 mg/kg", mech: "Inhibits platelet aggregation.", indications: "ACS, Stents.", contraindications: "Active bleed.", sideeffects: "Bleeding.", picco: "No hemodynamic effect.", rem: "Prodrug (needs liver activation)." },
    { s: "Ti", n: "Ticagrelor", cat: "c", trade: "Brilinta", grp: "Antiplatelet", sub: "P2Y12 block", ad: "90 mg BID", ch: "N/A", mech: "Reversible P2Y12 inhibitor.", indications: "ACS.", contraindications: "Intracranial bleed history.", sideeffects: "Dyspnea.", picco: "No hemodynamic effect.", rem: "Faster than Clopidogrel." },
    { s: "Wa", n: "Warfarin", cat: "c", trade: "Coumadin", grp: "Anticoag", sub: "VKA", ad: "2.5-10 mg", ch: "0.05-0.2 mg/kg", mech: "Vitamin K antagonist.", indications: "Valve replacement, AF.", contraindications: "Pregnancy.", sideeffects: "Bleeding.", picco: "No hemodynamic effect.", rem: "Monitor INR (2-3)." },
    { s: "Ri", n: "Rivaroxaban", cat: "c", trade: "Xarelto", grp: "NOAC", sub: "Xa inhibitor", ad: "15-20 mg QD", ch: "N/A", mech: "Direct Factor Xa inhibitor.", indications: "AF, DVT.", contraindications: "Renal failure (CrCl <15).", sideeffects: "Bleeding.", picco: "No hemodynamic effect.", rem: "No INR monitoring needed." },
    { s: "Ap", n: "Apixaban", cat: "c", trade: "Eliquis", grp: "NOAC", sub: "Xa inhibitor", ad: "5 mg BID", ch: "N/A", mech: "Direct Factor Xa inhibitor.", indications: "AF, DVT.", contraindications: "Active bleed.", sideeffects: "Bleeding.", picco: "No hemodynamic effect.", rem: "Best safety profile in NOACs." },
    { s: "Mg", n: "Magnesium", cat: "a", trade: "Magnesium", grp: "Ion", sub: "Cofactor", ad: "1-2 g IV", ch: "25-50 mg/kg", mech: "Stabilizes cardiac membrane.", indications: "Torsades de Pointes, Hypomagnesemia.", contraindications: "Heart block.", sideeffects: "Flushing, Hypotension.", picco: "May cause vasodilation (low SVRI) if given fast.", rem: "Drug of choice for Torsades." },
    { s: "Li", n: "Lidocaine", cat: "a", trade: "Lidocaine", grp: "Class Ib", sub: "Na-blocker", ad: "1-1.5 mg/kg", ch: "1 mg/kg", mech: "Blocks fast Na-channels.", indications: "Ventricular arrhythmias.", contraindications: "Heart block.", sideeffects: "Seizures, Confusion.", picco: "Minimal hemodynamic effect.", rem: "CNS toxicity risk." },
    { s: "Di", n: "Diltiazem", cat: "a", trade: "Dilatam", grp: "Class IV", sub: "Non-DHP CCB", ad: "0.25 mg/kg IV", ch: "N/A", mech: "Ca-channel blocker (Heart > Vessels).", indications: "AF rate control.", contraindications: "WPW, Heart failure (low EF).", sideeffects: "Bradycardia, hypotension.", picco: "Neg. inotrope: expect CI and HR decrease.", rem: "Israel: Dilatam." },
    { s: "Ve", n: "Verapamil", cat: "a", trade: "Ikacor", grp: "Class IV", sub: "Non-DHP CCB", ad: "5-10 mg IV", ch: "0.1-0.3 mg/kg", mech: "Ca-channel blocker (Potent Heart effect).", indications: "SVT, AF.", contraindications: "CHF, Beta-blocker use.", sideeffects: "Constipation, bradycardia.", picco: "Strong Neg. inotrope. Watch CI closely.", rem: "Israel: Ikacor." },
    { s: "Sp", n: "Spironolactone", cat: "d", trade: "Aldactone", grp: "MRA", sub: "Aldo-antag", ad: "25-50 mg QD", ch: "1-3 mg/kg", mech: "Aldosterone antagonist.", indications: "CHF, Ascites.", contraindications: "Hyperkalemia, Renal fail.", sideeffects: "Gynecomastia, Hyperkalemia.", picco: "Fluid management. Helps prevent remodeling.", rem: "Potassium sparing." },
    { s: "Hz", n: "HCTZ", cat: "d", trade: "Dizidex", grp: "Diuretic", sub: "Thiazide", ad: "12.5-25 mg QD", ch: "1-2 mg/kg", mech: "Distal tubule Na-Cl block.", indications: "HTN, mild edema.", contraindications: "Sulfa allergy.", sideeffects: "Hypokalemia, Hypercalcemia.", picco: "Mild preload reduction.", rem: "Ineffective if CrCl <30." },
    { s: "Np", n: "Nitroprusside", cat: "h", trade: "Nipride", grp: "Vasodilator", sub: "Balanced", ad: "0.3-5 ¬µg/kg/min", ch: "0.5-8 ¬µg/kg/min", mech: "NO donor. Potent arterial & venous dilation.", indications: "HTN crisis, Heart failure.", contraindications: "Renal/Hepatic failure (Cyanide risk).", sideeffects: "Cyanide toxicity, Thiocyanate tox.", picco: "Dramatic SVRI and Preload (GEDVI) reduction.", rem: "Light sensitive (wrap in foil)." },
    { s: "Et", n: "Etomidate", cat: "s", trade: "Etomidate", grp: "Sedative", sub: "GABA-A", ad: "0.2-0.3 mg/kg", ch: "0.2-0.3 mg/kg", mech: "Hypnotic. No analgesia.", indications: "RSI in unstable patients.", contraindications: "Sepsis (relative - adrenal suppression).", sideeffects: "Adrenal suppression, Myoclonus.", picco: "Most cardio-stable sedative. No change in CI/SVRI.", rem: "One dose only." },
    { s: "Ci", n: "Cisatracurium", cat: "r", trade: "Nimbex", grp: "Relaxant", sub: "Non-depol", ad: "0.15 mg/kg", ch: "0.1 mg/kg", mech: "Benzylisoquinolinium NMBA.", indications: "ARDS (ventilator synchrony).", contraindications: "Hypersensitivity.", sideeffects: "Bradycardia (rare).", picco: "No hemodynamic effect. Hofmann elimination.", rem: "Good for liver/renal failure." },
    { s: "Va", n: "Vasopressin", cat: "v", trade: "Empressin", grp: "Pressor", sub: "V1 agonist", ad: "0.01-0.04 U/min", ch: "0.0003-0.002 U/kg/min", mech: "V1 agonist. Non-adrenergic.", indications: "Septic Shock.", contraindications: "CAD.", sideeffects: "Ischemia.", picco: "SVRI increase, no tachycardia.", rem: "Fixed dose only." },
    { s: "An", n: "Angiotensin II", cat: "v", trade: "Giapreza", grp: "Pressor", sub: "RAS agonist", ad: "20-80 ng/kg/min", ch: "N/A", mech: "Direct AT1 receptor agonist.", indications: "Refractory Distributive Shock.", contraindications: "Thrombosis risk.", sideeffects: "Thrombosis, Acidosis.", picco: "Potent SVRI increase.", rem: "Very expensive, last resort." },
    { s: "Pr", n: "Propranolol", cat: "b", trade: "Deralin", grp: "Œ≤-blocker", sub: "Non-selective", ad: "10-40 mg PO", ch: "0.5-2 mg/kg", mech: "Non-selective Œ≤1/Œ≤2 block.", indications: "Thyroid storm, Portal HTN, Tremor.", contraindications: "Asthma.", sideeffects: "Bronchospasm.", picco: "Decreases CI/HR.", rem: "Crosses Blood-Brain Barrier." },
    { s: "Cr", n: "Carvedilol", cat: "b", trade: "Dimitone", grp: "Œ≤-blocker", sub: "Non-selective + Œ±1", ad: "3.125-25 mg BID", ch: "0.05 mg/kg", mech: "Œ≤1, Œ≤2 and Œ±1 block.", indications: "CHF, HTN.", contraindications: "Decompensated HF.", sideeffects: "Dizziness, Fatigue.", picco: "Decreases HR and SVRI (afterload).", rem: "Israel: Dimitone." },
    { s: "En", n: "Enalapril", cat: "h", trade: "Enaladex", grp: "ACEI", sub: "ACE inhibitor", ad: "5-20 mg QD", ch: "0.1 mg/kg", mech: "ACE inhibitor.", indications: "HTN, HF.", contraindications: "Pregnancy.", sideeffects: "Cough, Angioedema.", picco: "SVRI reduction.", rem: "Israel: Enaladex." },
    { s: "Lo", n: "Losartan", cat: "h", trade: "Ocsaar", grp: "ARB", sub: "AT1 blocker", ad: "25-100 mg QD", ch: "0.7 mg/kg", mech: "ARB.", indications: "HTN.", contraindications: "Pregnancy.", sideeffects: "Hyperkalemia.", picco: "SVRI reduction.", rem: "Israel: Ocsaar / Lotan." },
    { s: "Cn", n: "Candesartan", cat: "h", trade: "Atacand", grp: "ARB", sub: "AT1 blocker", ad: "8-32 mg QD", ch: "0.2 mg/kg", mech: "ARB.", indications: "CHF, HTN.", contraindications: "Pregnancy.", sideeffects: "Hyperkalemia.", picco: "SVRI reduction.", rem: "Israel: Atacand." },
    { s: "Id", n: "Isosorbide DN", cat: "h", trade: "Isoket", grp: "Nitrate", sub: "Vasodilator", ad: "20-120 mg/day", ch: "N/A", mech: "NO donor.", indications: "Angina, CHF.", contraindications: "Hypotension.", sideeffects: "Headache.", picco: "Preload reduction (GEDVI).", rem: "Israel: Isoket." },
    { s: "Fe", n: "Felodipine", cat: "h", trade: "Plandil", grp: "CCB", sub: "DHP", ad: "2.5-10 mg QD", ch: "N/A", mech: "DHP Calcium blocker.", indications: "HTN.", contraindications: "Hypotension.", sideeffects: "Edema.", picco: "SVRI reduction.", rem: "Israel: Plandil." },
    { s: "Ep", n: "Eplerenone", cat: "d", trade: "Inspra", grp: "MRA", sub: "Selective Aldo", ad: "25-50 mg QD", ch: "N/A", mech: "Selective aldosterone block.", indications: "Post-MI HF, CHF.", contraindications: "Hyperkalemia.", sideeffects: "Hyperkalemia.", picco: "Fluid management.", rem: "No gynecomastia." },
    { s: "To", n: "Torasemide", cat: "d", trade: "Examide", grp: "Diuretic", sub: "Loop", ad: "5-20 mg QD", ch: "N/A", mech: "Loop diuretic.", indications: "Edema, CHF.", contraindications: "Renal failure.", sideeffects: "Hypokalemia.", picco: "ELWI reduction.", rem: "More potent than Furosemide." },
    { s: "Da", n: "Dabigatran", cat: "c", trade: "Pradaxa", grp: "NOAC", sub: "IIa inhibitor", ad: "110-150 mg BID", ch: "N/A", mech: "Direct thrombin inhibitor.", indications: "AF, DVT.", contraindications: "CrCl <30.", sideeffects: "GI bleed.", picco: "No hemodynamic effect.", rem: "Reversal: Idarucizumab." },
    { s: "As", n: "Aspirin", cat: "c", trade: "Micropirin", grp: "Antiplatelet", sub: "COX-1 block", ad: "75-325 mg", ch: "3-5 mg/kg", mech: "Irreversible COX-1 block.", indications: "ACS, Stroke proph.", contraindications: "Asthma, Ulcer.", sideeffects: "GI bleed.", picco: "No hemodynamic effect.", rem: "Israel: Micropirin / Godamed." },
    { s: "Pn", n: "Phentolamine", cat: "h", trade: "Regitine", grp: "Œ±-blocker", sub: "Non-selective", ad: "5 mg IV", ch: "0.1 mg/kg", mech: "Non-selective Œ±-block.", indications: "Pheochromocytoma, Extravasation.", contraindications: "MI history.", sideeffects: "Tachycardia, Hypotension.", picco: "Sharp SVRI reduction.", rem: "Used for Ne/Ad extravasation." },
    { s: "Br", n: "Bridion", cat: "r", trade: "Sugammadex", grp: "Relaxant", sub: "Reversal", ad: "2-4 mg/kg", ch: "2-4 mg/kg", mech: "Chelating agent for Roc/Vec.", indications: "NMB Reversal.", contraindications: "Renal failure.", sideeffects: "Hypersensitivity.", picco: "No hemodynamic effect.", rem: "Very fast reversal." },
    { s: "Fi", n: "Fentanyl", cat: "s", trade: "Fentanyl", grp: "Analgesic", sub: "Opioid", ad: "25-100 ¬µg/hr", ch: "1-5 ¬µg/kg/hr", mech: "Œº-opioid agonist.", indications: "Pain, Sedation adjunct.", contraindications: "Resp. failure.", sideeffects: "Chest wall rigidity (high dose).", picco: "Stable CI. May lower HR.", rem: "100x stronger than Morphine." },
    { s: "Mo", n: "Morphine", cat: "s", trade: "Morphine", grp: "Analgesic", sub: "Opioid", ad: "2-10 mg IV", ch: "0.1 mg/kg", mech: "Opioid agonist. Histamine release.", indications: "ACS, Pain, Pulmonary Edema.", contraindications: "Asthma.", sideeffects: "Hypotension, Nausea.", picco: "Vasodilation (histamine). Reduces Preload.", rem: "Gold standard for pain." },
    { s: "Th", n: "Thiopental", cat: "s", trade: "Pentothal", grp: "Sedative", sub: "Barbiturate", ad: "3-5 mg/kg", ch: "3-5 mg/kg", mech: "GABA-A facilitator.", indications: "ICP control, Status Epilepticus.", contraindications: "Porphyria.", sideeffects: "Profound hypotension.", picco: "Sharp SVRI and CI decrease.", rem: "Brain protection." },
    { s: "Di", n: "Digoxin", cat: "i", trade: "Lanoxin", grp: "Inotrope", sub: "Na/K-ATPase", ad: "0.125-0.25 mg", ch: "10-30 ¬µg/kg", mech: "Inhibits Na/K-ATPase. Increases Ca.", indications: "AF rate control, HF.", contraindications: "AV block, WPW.", sideeffects: "Toxicity (yellow vision).", picco: "Pos. inotrope (GEF) + Neg. chronotrope (HR).", rem: "Narrow therapeutic window." },
    { s: "Tr", n: "Terlipressin", cat: "v", trade: "Glypressin", grp: "Pressor", sub: "V1 agonist", ad: "1-2 mg IV", ch: "N/A", mech: "Synthetic vasopressin analogue.", indications: "Variceal bleed, HRS.", contraindications: "Pregnancy, CAD.", sideeffects: "Abdominal pain.", picco: "SVRI increase, CI decrease.", rem: "Longer half-life than VP." }
];

        const grid = document.getElementById('drugGrid');
        const tooltip = document.getElementById('tooltip');

        function init() {
            drugs.forEach(d => {
                const card = document.createElement('div');
                card.className = `drug-card cat-${d.cat}`;
                card.innerHTML = `
                    <div class="card-top">${d.grp}<br>${d.sub}</div>
                    <div class="card-mid">
                        <div class="drug-symbol">${d.s}</div>
                        <div class="drug-name">${d.n}</div>
                    </div>
                    <div class="card-bottom">
                        Ad: ${d.ad}<br>
                        <span class="peds-label">Peds: ${d.ch}</span>
                    </div>
                `;
                card.onmouseenter = (e) => showTooltip(e, d);
                card.onmousemove = moveTooltip;
                card.onmouseleave = hideTooltip;
                grid.appendChild(card);
            });
        }

        function showTooltip(e, d) {
            tooltip.style.display = 'block';
            tooltip.innerHTML = `
                <div class="tt-title">${d.n}</div>
                <div class="tt-trade">IL Trade Name: ${d.trade}</div>
                
                <span class="tt-label">Mechanism of Action</span>
                <div class="tt-content">${d.mech}</div>
                
                <span class="tt-label">Indications</span>
                <div class="tt-content">${d.indications}</div>

                <span class="tt-label">PiCCO Clinical Insights</span>
                <div class="tt-picco">${d.picco}</div>
                
                <span class="tt-label">Side Effects & Contraindications</span>
                <div class="tt-content">${d.sideeffects} <br><strong>Contra:</strong> ${d.contraindications}</div>
                
                <span class="tt-label">Dosing (Adult / Peds)</span>
                <div class="tt-content"><strong>Adults:</strong> ${d.ad} <br><strong>Pediatrics:</strong> ${d.ch}</div>

                <span class="tt-label">Clinical Remarks</span>
                <div class="tt-content">${d.rem}</div>
            `;
            moveTooltip(e);
        }

        function moveTooltip(e) {
            let x = e.clientX + 20;
            let y = e.clientY + 20;
            if (x + 450 > window.innerWidth) x = e.clientX - 470;
            if (y + 500 > window.innerHeight) y = e.clientY - 520;
>>>>>>> 423490dbb2ae748f4e57e59325f64b7311c0f258
            tooltip.style.left = x + 'px';
            tooltip.style.top = y + 'px';
        }

<<<<<<< HEAD
        function hideTooltip() {
            tooltip.classList.remove('active');
        }
    </script>
    <script src="../JS/search.js"></script>
    <script src="../JS/main.js"></script>
</body>
</html>
=======
        function hideTooltip() { tooltip.style.display = 'none'; }

        // –õ–æ–≥–∏–∫–∞ –ø–µ—Ä–µ–∫–ª—é—á–µ–Ω–∏—è —Ç–µ–º –∏–∑ —à–∞–±–ª–æ–Ω–∞
        const themeBtn = document.getElementById('theme-switcher');
        const sunIcon = themeBtn.querySelector('.icon-sun');
        const moonIcon = themeBtn.querySelector('.icon-moon');

        themeBtn.onclick = () => {
            document.body.classList.toggle('light-theme');
            document.body.classList.toggle('dark-theme');
            const isLight = document.body.classList.contains('light-theme');
            sunIcon.style.display = isLight ? 'none' : 'inline';
            moonIcon.style.display = isLight ? 'inline' : 'none';
        };

        // –ë—É—Ä–≥–µ—Ä –º–µ–Ω—é
        document.getElementById('menu-toggle').onclick = function() {
            document.getElementById('main-nav').classList.toggle('active');
        };

        init();
    </script>
</body>
</html>
>>>>>>> 423490dbb2ae748f4e57e59325f64b7311c0f258
